US20030021854A1 - Method of induction of apoptosis and inhibition of matrix metalloproteinases using antimicrobial metals - Google Patents

Method of induction of apoptosis and inhibition of matrix metalloproteinases using antimicrobial metals Download PDF

Info

Publication number
US20030021854A1
US20030021854A1 US10131568 US13156802A US2003021854A1 US 20030021854 A1 US20030021854 A1 US 20030021854A1 US 10131568 US10131568 US 10131568 US 13156802 A US13156802 A US 13156802A US 2003021854 A1 US2003021854 A1 US 2003021854A1
Authority
US
Grant status
Application
Patent type
Prior art keywords
method
antimicrobial
set forth
nanocrystalline
antimicrobial metal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10131568
Inventor
Robert Burrell
John Wright
Kan Lam
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NUCRYST PHARMACEUTICALS CORP
Original Assignee
NUCRYST PHARMACEUTICALS CORP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES, AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N59/00Biocides, pest repellants or attractants, or plant growth regulators containing elements or inorganic compounds
    • A01N59/16Heavy metals; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/38Silver; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/40Peroxides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007Drug-containing films, membranes or sheets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L15/00Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42Use of materials characterised by their function or physical properties
    • A61L15/46Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L17/00Materials for surgical sutures or for ligaturing blood vessels ; Materials for prostheses or catheters
    • A61L17/14Post-treatment to improve physical properties
    • A61L17/145Coating
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/28Materials for coating prostheses
    • A61L27/30Inorganic materials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L29/00Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/08Materials for coatings
    • A61L29/10Inorganic materials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/08Materials for coatings
    • A61L31/082Inorganic materials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/10Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
    • A61L2300/102Metals or metal compounds, e.g. salts such as bicarbonates, carbonates, oxides, zeolites, silicates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/10Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
    • A61L2300/102Metals or metal compounds, e.g. salts such as bicarbonates, carbonates, oxides, zeolites, silicates
    • A61L2300/104Silver, e.g. silver sulfadiazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/404Biocides, antimicrobial agents, antiseptic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/452Lubricants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/606Coatings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/62Encapsulated active agents, e.g. emulsified droplets
    • A61L2300/624Nanocapsules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/63Crystals
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00Drug, bio-affecting and body treating compositions
    • Y10S424/15Suppositories
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S514/00Drug, bio-affecting and body treating compositions
    • Y10S514/825Arthritis
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S514/00Drug, bio-affecting and body treating compositions
    • Y10S514/826Asthma
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S514/00Drug, bio-affecting and body treating compositions
    • Y10S514/829Bite or sting
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S514/00Drug, bio-affecting and body treating compositions
    • Y10S514/829Bite or sting
    • Y10S514/83Bite or sting insect
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S514/00Drug, bio-affecting and body treating compositions
    • Y10S514/849Cough and cold preparation
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S514/00Drug, bio-affecting and body treating compositions
    • Y10S514/851Cystic fibrosis
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S514/00Drug, bio-affecting and body treating compositions
    • Y10S514/853Decongestant
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S514/00Drug, bio-affecting and body treating compositions
    • Y10S514/857Dermatitis
    • Y10S514/861Eczema
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S514/00Drug, bio-affecting and body treating compositions
    • Y10S514/857Dermatitis
    • Y10S514/862Poison ivy, oak or sumac
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S514/00Drug, bio-affecting and body treating compositions
    • Y10S514/857Dermatitis
    • Y10S514/864Seborrhea
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S514/00Drug, bio-affecting and body treating compositions
    • Y10S514/857Dermatitis
    • Y10S514/865Diaper rash
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S514/00Drug, bio-affecting and body treating compositions
    • Y10S514/88Hair treatment, application to head or scalp
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S514/00Drug, bio-affecting and body treating compositions
    • Y10S514/88Hair treatment, application to head or scalp
    • Y10S514/881Shampoo
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S514/00Drug, bio-affecting and body treating compositions
    • Y10S514/882Hemorrhoid preparation
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S514/00Drug, bio-affecting and body treating compositions
    • Y10S514/886Inflammation, skin
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S514/00Drug, bio-affecting and body treating compositions
    • Y10S514/886Inflammation, skin
    • Y10S514/887Topical treatment
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S514/00Drug, bio-affecting and body treating compositions
    • Y10S514/8995Mouth treatment
    • Y10S514/90Treatment or prevention of periodontisis
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S514/00Drug, bio-affecting and body treating compositions
    • Y10S514/8995Mouth treatment
    • Y10S514/901Mouthwash for mouth treatment
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S514/00Drug, bio-affecting and body treating compositions
    • Y10S514/8995Mouth treatment
    • Y10S514/902Treatment or prevention of gingiva
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S514/00Drug, bio-affecting and body treating compositions
    • Y10S514/912Ophthalmic
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S514/00Drug, bio-affecting and body treating compositions
    • Y10S514/912Ophthalmic
    • Y10S514/914Inflammation
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S514/00Drug, bio-affecting and body treating compositions
    • Y10S514/925Ulcer treatment
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S514/00Drug, bio-affecting and body treating compositions
    • Y10S514/931Veneral disease
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S514/00Drug, bio-affecting and body treating compositions
    • Y10S514/931Veneral disease
    • Y10S514/932Gonorrhea
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S514/00Drug, bio-affecting and body treating compositions
    • Y10S514/931Veneral disease
    • Y10S514/933Syphilis
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S514/00Drug, bio-affecting and body treating compositions
    • Y10S514/931Veneral disease
    • Y10S514/934Virus
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S514/00Drug, bio-affecting and body treating compositions
    • Y10S514/944Gel
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S514/00Drug, bio-affecting and body treating compositions
    • Y10S514/951Powders, granules or particles of specified mesh or particle size
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S514/00Drug, bio-affecting and body treating compositions
    • Y10S514/953Shaped forms adapted for noningestible use other than suppository type, e.g. films, inserts
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S514/00Drug, bio-affecting and body treating compositions
    • Y10S514/953Shaped forms adapted for noningestible use other than suppository type, e.g. films, inserts
    • Y10S514/954Ocular
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S514/00Drug, bio-affecting and body treating compositions
    • Y10S514/953Shaped forms adapted for noningestible use other than suppository type, e.g. films, inserts
    • Y10S514/956Aural or otic, i.e. ear
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S514/00Drug, bio-affecting and body treating compositions
    • Y10S514/958Drug, bio-affecting and body treating compositions for smoking or inhaling
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S514/00Drug, bio-affecting and body treating compositions
    • Y10S514/964Sustained or differential release type
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S514/00Drug, bio-affecting and body treating compositions
    • Y10S514/964Sustained or differential release type
    • Y10S514/965Discrete particles in supporting matrix
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S514/00Drug, bio-affecting and body treating compositions
    • Y10S514/966Rectal
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S514/00Drug, bio-affecting and body treating compositions
    • Y10S514/967Vaginal
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S514/00Drug, bio-affecting and body treating compositions
    • Y10S514/968Urethral
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S514/00Drug, bio-affecting and body treating compositions
    • Y10S514/969Ointment or salve base
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00Stock material or miscellaneous articles
    • Y10T428/31504Composite [nonstructural laminate]
    • Y10T428/31855Of addition polymer from unsaturated monomers

Abstract

The invention relates to a method to induce apoptosis and to inhibit matrix metalloproteinases in a disease condition in a human or animal by contacting hyperplastic tissue, tumor tissue, or a cancerous lesion with one or more antimicrobial metals, preferably formed with atomic disorder, and preferably in a nanocrystalline form. The nanocrystalline antimicrobial metal of choice may be used in the form of a nanocrystalline coating of one or more antimicrobial metals, a nanocrystalline powder of one or more antimicrobial metals, or a solution containing dissolved species from a nanocrystalline powder or coating of one or more antimicrobial metals.

Description

    CROSS-REFERENCE TO RELATED APPLICATIONS
  • This application is a Continuation-in-Part of co-pending U.S. patent application Ser. No. 09/840,637 filed Apr. 23, 2001. This application also claims priority from U.S. Provisional Patent Application No. 60/285,884, filed Apr. 23, 2001. To the extent that they are consistent herewith, the aforementioned applications are incorporated herein by reference.[0001]
  • FIELD OF THE INVENTION
  • The present invention provides a method to induce apoptosis and to inhibit matrix metalloproteinases in a disease condition in a human or animal by contacting hyperplastic tissue, tumor tissue, or a cancerous lesion with antimicrobial metals; methods for the preparation of the antimicrobial metals; pharmaceutical compositions comprising same; and uses thereof. [0002]
  • BACKGROUND OF THE INVENTION
  • Apoptosis and matrix metalloproteinases (MMPs) have been implicated in many pathological diseases, such as cancer. Apoptosis or programmed cell death is a system which removes unnecessary, aged, or damaged cells. Apoptosis occurs during development to ensure proper formation of the fingers and toes in the fetus and of synapses between neurons in the brain; and serves to eradicate virus-infected cells, unnecessary immune cells, cells with DNA damage, and cancer cells. Decreased apoptosis has been implicated in developmental malformation, cancer and autoimmune disease, while enhanced apoptosis has been associated with degenerative diseases such as Alzheimer's disease, AIDS dementia, and Huntington's disease. [0003]
  • Caspases are a family of proteases, including initiator (activator) and effector (executioner) protease types, which regulate proteolysis during apoptosis. Apoptosis is triggered by signals which are either internal or external to the cell. In a healthy cell, the protein Bcl-2 is expressed on the surface and is bound to the protein Apaf-1. Internal damage in the cell causes Bcl-2 to release Apaf-1 and to no longer keep cytochrome c from leaking out of the mitochondria. The released cytochrome c and Apaf-1 bind to molecules of caspase 9. The resulting complex of cytochrome c, Apaf-1, caspase 9, and ATP aggregates in the cytosol. In cleaving a protein, caspase 9 activates other caspases, leading to digestion of structural proteins on the cytoplasm, degradation of chromosomal DNA, and phagocytosis of the cell. With regard to external signals (e.g., as in cytotoxic T cells inducing apoptosis in a virus-infected cell), binding of a death activator (FasL and TNF) to the Fas and TNF receptor proteins on the surface of a target cell activates caspase 8, which activates other caspases leading to phagocytosis of the target cell. [0004]
  • Cancer cells may have mechanisms to avoid apoptosis. For example, some B-cell leukemias and lymphomas express high levels of Bcl-2, thus blocking apoptotic signals they may receive. Melanoma cells avoid apoptosis by inhibiting the expression of the gene which encodes Apaf-1. Lung and colon cancer cells secrete a molecule which binds to FasL, inhibiting its binding to Fas. Currently, radiation and standard chemotherapeutic drugs are used to induce apoptosis in some types of cancer cells; however, with such treatments having undesirable side effects and some cancers being resistant to such therapies, there exists a need to provide an effective approach which lacks such side effects, and demonstrates minimal interference with normal cell function. [0005]
  • Cancer tissue may also be treated with inhibitors of MMPs. MMPs have been associated with diseases associated with the excessive degradation of extracellular matrix, such as tumor invasion and metastasis, arthritic diseases (rheumatoid arthritis and osteoarthritis), bone resorptive diseases (such as osteoporosis), enhanced collagen destruction associated with diabetes, periodontal disease, corneal ulceration, and ulceration of the skin. MMPs are a family of at least 20 enzymes (proteases) which are involved in the degradation of connective tissues, such as collagen, elastins, fibronectin, laminin, and other components of the extracellular matrix. Such components are present in the linings of joints, interstitial connective tissues, basement membranes, and cartilage. MMPs are present in various cell types which reside in or are associated with connective tissue, such as fibroblasts, monocytes, macrophages, endothelial cells, and invasive or metastatic tumor cells. Expression of MMPs may be induced by a variety of factors, including growth factors, cytokines, chemical agents, physical stress, cell-matrix interactions, cell-cell interactions and oncogenic transformation. The MMP family includes collagenases, gelatinases, stromelysins and stromelysin-like proteases as follows: [0006]
  • i) Collagenases include MMP-1 (interstitial), MMP-8 (neutrophil), and MMP-13, which catalyze the initial degradation of native collagen types I, II, III and VII. Collagen is an essential component of the extracellular matrix of tissues such as cartilage, bone, tendon and skin. MMP-13 is associated with osteoarthritis, ulcers and malignant tumor invasion. [0007]
  • ii) Gelatinases include MMP-2 (secreted by fibroblasts and a wide variety of other cell types) and MMP-9 (released by mononuclear phagocytes, neutrophils, corneal epithelial cells, tumor cells, cytotrophoblasts and keratinocytes). The gelatinases degrade gelatins (denatured collagens) and collagen type IV (basement membrane). [0008]
  • iii) Stromelysins include MMP-3, MMP-10 and MMP-11. MMP-3 and MMP-10 are expressed by epithelial cells and carcinomas, and degrade a broad range of extracellular matrix substrates, including laminin, fibronectin, proteoglycans, and collagen types IV and IX. MMP-11 is expressed by fibroblasts, and cleaves serine protease inhibitors. [0009]
  • iv) Stromelysin-like MMPs include MMP-12 and MMP-7. MMP-12 is expressed by macrophages and stromal cells, and degrades elastin. MMP-7 or matrilysin is expressed by mononuclear phagocytes and sporadically in tumors, and degrades a wide range of matrix substrates including proteoglycans, gelatins, fibronectin, elastin, and laminin. [0010]
  • Inhibitors of MMPs may serve as potential therapeutic agents. However, certain hydroxamic acids and derivatives thereof which have been suggested as collagenase inhibitors appear to be potentially toxic due to the hydroxamic moeity. There thus exists a need for a non-toxic, effective treatment to inhibit MMPs. [0011]
  • A treatment which provides a two-fold approach, namely induction of apoptosis of particular cells and inhibition of MMPs to eradicate cancer cells, and to reduce tissue damage contributing to tumor invasion and metastasis, may be desirable. Currently, cis-platin and its variations have been used as pro-apoptotic, anti-cancer agents, since the platinum complex attacks the DNA of tumor cells, thus disrupting RNA synthesis. However, cis-platin can pass through the blood to the kidneys and be immediately excreted; bind to proteins and be rendered inactive before reaching the tumor cells; or attack cells which are not tumors. Since acute toxicity may occur with long term use, cis-platin is restricted to short term, high doses. Sustained release to maintain treatment efficacy and non-toxicity in an anti-tumor agent are desirable. [0012]
  • While the patent literature reports that silver metal or silver salts such as silver nitrate, silver halides or silver sulphadiazine are among useful antibacterial agents, they have not, to the inventors' knowledge, been known or adopted to induce apoptosis and/or inhibit MMPs. For tumor tissue and cancerous lesions, there may be benefits associated with enhanced cellular apoptosis and reduced levels of MMPs; for example, induction of apoptosis may aid in tumor suppression by eradicating tumor cells and by reducing the chance of tumor invasion and metastasis through inhibition of MMPs. In addition to affecting cancer cells, such treatment may be beneficial in eradicating excessive, normal cells, as in hyperplastic tissue in which abnormal multiplication or increase in the number of cells in a normal arrangement in normal tissue or an organ has occurred. [0013]
  • SUMMARY OF THE INVENTION
  • The inventors have established that antimicrobial metals formed with atomic disorder and preferably in a nanocrystalline form, induce apoptosis and inhibit MMPs. Treatment of hyperplastic tissue, tumor tissue, or cancerous lesions with antimicrobial metals having pro-apoptotic and anti-MMP effects is thereby indicated. This new treatment will have the dual advantages of being both pro-apoptotic and an inhibitor of MMPs. Methods and formulations of this invention have application to both humans and animals. [0014]
  • The antimicrobial metals selected from one or more of silver, gold, platinum and palladium, are formed with atomic disorder, such that ions, clusters, atoms or molecules of the metals are released at a concentration sufficient to provide localized pro-apoptotic and anti-MMP effects. Most preferably, the antimicrobial metals are in a nanocrystalline form, and include sufficient atomic disorder to provide such effects on a sustainable basis. [0015]
  • Without being bound by the same, it is believed that the nanocrystalline antimicrobial metals formed with atomic disorder are capable of releasing highly active clusters of the antimicrobial metal (example clusters of Ag[0016] 0 or Ag+/Ag0), which are responsible for the surprisingly enhanced antimicrobial activity and the surprising presence of the anti-inflammatory activity in the treatment of mucosal membranes, compared with other known antimicrobials such as silver salts (ex. silver nitrate), silver zeolites which release only Ag+, or silver metal and silver oxide which have only minor solubility. Clusters are known to be small groups of atoms, ions or the like, as described by R. P. Andres et al., “Research Opportunities on Cluster and Cluster-Assembled Materials”, J. Mater. Res. Vol 4, No 3, 1989, p. 704. For silver, clusters are believed to contain less than the 14 atoms of a normal face centered cubic crystal lattice form of silver.
  • The crystalline forms of these antimicrobial metals may be used in, or formulated from, any of the following formats: [0017]
  • i) coatings of the antimicrobial metals on medical grade substrates, for example, dressings, packings, meshes, films, filtering surfaces, filters, infusers, fibres, containers or vials, from materials composed of for example polyethylene, high density polyethylene, polyvinylchloride, latex, silicone, cotton, rayon, polyester, nylon, cellulose, acetate, carboxymethylcellulose, alginate, chitin, chitosan and hydrofibres; [0018]
  • ii) powders, preferably prepared as nanocrystalline powders of the antimicrobial metals, or as nanocrystalline coatings of the antimicrobial metals on biocompatible substrates in powder form, preferably on bioabsorbable and/or hygroscopic substrates such as: [0019]
  • Synthetic Bioabsorbable Polymers: for example polyesters/polyactones such as polymers of polyglycolic acid, glycolide, lactic acid, lactide, dioxanone, trimethylene carbonate etc., polyanhydrides, polyesteramides, polyortheoesters, polyphosphazenes, and copolymers of these and related polymers or monomers, or [0020]
  • Naturally Derived Polymers: [0021]
  • Proteins: albumin, fibrin, collagen, elastin; [0022]
  • Polysaccharides: chitosan, alginates, hyaluronic acid; and [0023]
  • Biosynthetic Polyesters: 3-hydroxybutyrate polymers; [0024]
  • iii) occlusions or hydrated dressings, in which the dressing is impregnated with a powder or solution of the antimicrobial metals, or is used with a topical formulation of the antimicrobial metals, with such dressings for example as hydrocolloids, hydrogels, polyethylene, polyurethane, polyvinylidine, siloxane or silicone dressings; [0025]
  • iv) gels, formulated with nanocrystalline powders or solutions of the antimicrobial metals with such materials as carboxymethylcellulose, alginate, chitin, chitosan and hydrofibres, together with such ingredients as preservatives, pectin and viscosity enhancers; [0026]
  • v) creams, lotions, pastes and ointments formulated with nanocrystalline powders or solutions of the antimicrobial metals, for example as emulsions or with drying emollients; and [0027]
  • vi) liquids, formulated as solutions by dissolving nanocrystalline coatings or powders of the antimicrobial metals, for example as topical solutions, aerosols, mists, sprays, drops, infusions and instillation solutions for body cavities such as the bladder, prostate, lung, and liver. [0028]
  • Solutions of the antimicrobial metals lose some activity with aging and are thus either stabilized or generated fresh for administration. Alternatively, the antimicrobial metals may be packaged for convenient solution generation, for instance in a pervious membrane such as a tea bag type infuser. Other two part or two phase systems may be used in which the nanocrystalline metal is separated from the water or electrolyte solvent, for example in kit form, with the antimicrobial metal being provided in dissolving capsules, as a coating on the inside of vials or containers, on substrates such as dressing, separated by a membrane which can be perforated, or in a separate container from the carrier, in a tea bag-type infuser etc. [0029]
  • In the above formats, the nanocrystalline antimicrobial metals are formulated from nanocrystalline coatings or nanocrystalline powders of the nanocrystalline antimicrobial metals, or from solutions prepared by dissolving the nanocrystalline coatings or powders therein. The formulations include a therapeutically effective amount of the coatings or powders, and most preferably, the following amounts: [0030]
    For coatings: 150-3000 nm thick coatings for substrates, or thicker
    for forming powders (such coatings can be used to
    generate 0.001 to 10% by weight solutions)
    For gels, creams 0.01-30% by weight, more preferably 0.01-10% by
    etc.: weight and most preferably 0.1-5% by weight of the
    antimicrobial or noble metal powder
    For liquids: 0.001-10% by weight, more preferably 0.01 to 5% by
    weight and most preferably 0.1 to 1% by weight of the
    antimicrobial or noble metal (generated from any
    format, including coatings, flakes, powders).
  • Concentrations of the antimicrobial or noble metal species in solution will vary according to the application, formulation and subject, but will generally range from 1-5000 μg/ml, more preferably 20-3000 μg/ml, more preferably 40-800 μg/ml, and most preferably 50-500 μg/ml. [0031]
  • Nanocrystalline coatings of the antimicrobial metals are most preferably deposited onto substrates such as dressings, for example one or more layers of medical dressing materials which can be laminated with uncoated layers of medical dressing materials. The coatings can be prepared by known techniques for preparing nanocrystalline coatings, but are most preferably prepared by physical vapour deposition under conditions which create atomic disorder. The nanocrystalline coatings may be prepared to create an interference colour so as to provide an indicator, as described in prior patent application WO 98/41095, published Sep. 24, 1998, and naming inventors R. E. Burrell and R. J. Precht. [0032]
  • Nanocrystalline powders of the antimicrobial metals may be prepared as nanocrystalline coatings, preferably of the above thickness, on powdered substrates such as chitin, or may be prepared as nanocrystalline coatings on a substrate such as a silicon wafer, and then scraped off as a nanocrystalline powder. Alternatively, fine grained or nanocrystalline powders of the antimicrobial metals may be cold worked to impart atomic disorder, as taught in prior patent applications WO 93/23092, published Nov. 25, 1993, and WO 95/13704, published May 26, 1995, both of which name Burrell et al., as inventors. [0033]
  • Thus, the invention broadly provides a method of inducing apoptosis in a disease condition in a human or an animal, which comprises: [0034]
  • contacting a hyperplastic tissue, a tumor tissue, or a cancerous lesion with a therapeutically effective amount of the antimicrobial metals in a crystalline form to provide a localized pro-apoptotic effect, wherein the antimicrobial metals are characterized by sufficient atomic disorder, such that the metal, in contact with an alcohol or water-based electrolyte, releases atoms, ions, molecules, or clusters of at least one antimicrobial metal at a concentration sufficient to provide a localized pro-apoptotic effect. The antimicrobial metals further inhibit one or more matrix metalloproteinases or modulate the production of the one or more matrix metalloproteinases. [0035]
  • As used herein and in the claims, the terms and phrases set out below have the meanings which follow. [0036]
  • “Apoptosis” means programmed cell death which removes unnecessary, aged, or damaged cells. [0037]
  • “Pro-apoptotic effect” means that atoms, ions, molecules or clusters of the antimicrobial or noble metal are released to contact a human or animal cell in a concentration sufficient to induce apoptosis. [0038]
  • “Anti-MMP effect” means that atoms, ions, molecules or clusters of the antimicrobial or noble metal are released to contact a human or animal cell in a concentration sufficient to inhibit one or more matrix metalloproteinases or modulate the production of one or more matrix metalloproteinases. [0039]
  • “Matrix metalloproteinases” is meant to refer to any protease of the family of MMPs which are involved in the degradation of connective tissues, such as collagen, elastins, fibronectin, laminin, and other components of the extracellular matrix, and associated with conditions in which excessive degradation of extracellular matrix occurs, such as tumor invasion and metastasis. [0040]
  • “Gelatinases” is meant to refer to MMP-2 (secreted by fibroblasts and a wide variety of other cell types) and MMP-9 (released by mononuclear phagocytes, neutrophils, corneal epithelial cells, tumor cells, cytotrophoblasts and keratinocytes). The gelatinases degrade gelatins (denatured collagens) and collagen type IV (basement membrane). [0041]
  • “Fibroblast” means a connective tissue cell which is a flat-elongated cell with cytoplasmic processes at each end having a flat, oval vesicular nucleus. Fibroblasts which differentiate into chondroblasts, collagenoblasts, and osteoblasts form the fibrous tissues in the body, tendons, aponeuroses, supporting and binding tissues of all sorts. [0042]
  • “Neutrophil” means a granulocyte which arises from the bone marrow and is fully mature when it is released into the circulation. It functions in cellular defense primarily in phagocytosis. [0043]
  • “Polymorphonuclear leukocyte” is meant to refer to neutrophils. The name derives from the multiple lobes of the mature neutrophil's nucleus. [0044]
  • “Hyperplasia” means abnormal multiplication or increase in the number of cells in a normal arrangement in normal tissue or an organ. [0045]
  • “Tumor” means a spontaneous growth of tissue in which multiplication of cells is abnormal, uncontrolled and progressive. A tumor serves no useful function and grows at the expense of the healthy organism. [0046]
  • “Malignant” means a tumor which has the properties of anaplasia, invasion, and metastasis. [0047]
  • “Benign” means a tumor which is not malignant, recurrent, invasive, or progressive. A tumor or growth which is benign is noncancerous. [0048]
  • “Cancerous lesion” means a tumor of epithelial tissue, or malignant, new growth made up of epithelial cells tending to infiltrate surrounding tissues and to give rise to metastases. As used in reference to the skin, a cancerous lesion means a lesion which may be a result of a primary cancer, or a metastasis to the site from a local tumor or from a tumor in a distant site. It may take the form of a cavity, an open area on the surface of the skin, skin nodules, or a nodular growth extending from the surface of the skin. [0049]
  • “Metastasis” means the movement or spreading of cancer cells from one organ or tissue to another via the bloodstream, or lymph system. [0050]
  • “Metal” or “metals” includes one or more metals whether in the form of substantially pure metals, alloys or compounds such as oxides, nitrides, borides, sulphides, halides or hydrides. [0051]
  • “Antimicrobial metals” are silver, gold, platinum, palladium, iridium, zinc, copper, tin, antimony, bismuth, or mixtures of these metals with same or other metals, silver, gold, platinum and palladium being preferred, and silver being most preferred. [0052]
  • “Noble metals” are silver, gold, platinum and palladium, or mixtures of such metals with same or other metals, with silver metal being the most preferred. [0053]
  • “Antimicrobial effect” means that atoms, ions, molecules or clusters of the antimicrobial or noble metal are released into the electrolyte which the coating contacts in concentration sufficient to inhibit microbial growth on and in the vicinity of the coating. The most common methods of measuring an antimicrobial effect are a zone of inhibition test (which indicates an inhibitory effect, whether microbiostatic or microbiocidal) or a logarithmic reduction test (which indicates a microbiocidal effect). In a zone of inhibition test (ZOI) the material to be tested is placed on a bacterial lawn (or a lawn of other microbial species) and incubated. A relatively small or no ZOI (ex. less than 1 nun) indicates a non-useful antimicrobial effect, while a larger ZOI (ex. greater than 5 mm) indicates a highly useful antimicrobial effect. The ZOI is generally reported as a corrected zone of inhibition (CZOI), wherein the size of the test sample is subtracted from the zone. A logarithmic reduction test in viable bacteria is a quantitative measure of the efficacy of an antibacterial treatment; for example, a 5 log reduction means a reduction in the number of microorganisms by 100,000-fold (e.g., if a product contained 100,000 pertinent microorganisms, a 5 log reduction would reduce the number of pertinent microorganisms to 1). Generally, a 3 log reduction represents a bactericidal effect. The logarithmic reduction test involves combining the inoculum with the test treatment, incubating the inoculum with the test treatment, recovering the bacteria or other microbial species, and enumerating the bacteria or other microbial species using serial dilutions. Examples of these tests are set out in the examples which follow. [0054]
  • “Biocompatible” means generating no significant undesirable host response for the intended utility. Most preferably, biocompatible materials are non-toxic for the intended utility. Thus, for human utility, biocompatible is most preferably non-toxic to humans or human tissues. [0055]
  • “Sustained release” or “sustainable basis” are used to define release of atoms, molecules, ions or clusters of an antimicrobial metal that continues over time measured in hours or days, and thus distinguishes release of such metal species from the bulk metal, which release such species at a rate and concentration which is too low to be therapeutically effective, and from highly soluble salts of antimicrobial metals such as silver nitrate, which releases silver ions virtually instantly, but not continuously, in contact with an alcohol or electrolyte. [0056]
  • “Atomic disorder” includes high concentrations one or more of: point defects in a crystal lattice, vacancies, line defects such as dislocations, interstitial atoms, amorphous regions, grain and sub grain boundaries and the like relative to its normal ordered crystalline state. Atomic disorder leads to irregularities in surface topography and inhomogeneities in the structure on a nanometer scale. [0057]
  • “Normal ordered crystalline state” means the crystallinity normally found in bulk metal materials, alloys or compounds formed as cast, wrought or plated metal products. Such materials contain only low concentrations of such atomic defects as vacancies, grain boundaries and dislocations. [0058]
  • “Diffusion”, when used to describe conditions which limit diffusion in processes to create and retain atomic disorder, i.e. which freeze-in atomic disorder, means diffusion of atoms (adatom diffusion) and/or molecules on the surface or in the matrix of the material being formed. [0059]
  • “Alcohol or water-based electrolyte” is meant to include any alcohol or water-based electrolyte that the antimicrobial materials of the present invention might contact in order to activate (i.e. cause the release of species of the antimicrobial metal) into same. The term is meant to include alcohols (short chain (C[0060] 6 or less) and preferably C4 or less), water, gels, fluids, solvents, and tissues containing, secreting, or exuding water or water-based electrolytes, including body fluids (for example blood, urine, or saliva), and body tissue (for example skin).
  • “Bioabsorbable” as used herein in association includes substrates which are useful in medical devices, that is which are biocompatible, and which are capable of bioabsorption in period of time ranging from hours to years, depending on the particular application. [0061]
  • “Bioabsorption” means the disappearance of materials from their initial application site in the body (human or mammalian) with or without degradation of the dispersed polymer molecules. [0062]
  • “Colour change” is meant to include changes of intensity of light under monochromatic light as well as changes of hue from white light containing more than one wavelength. [0063]
  • An “interference colour” is produced when light impinges on two or more partly reflective surfaces separated by a distance which bears the right relationship to the wavelength of the light to be removed by destructive interference. [0064]
  • “Partly reflective” when used to describe the base or top layer materials, means that the material has a surface which reflects a portion of incident light, but which also transmits a portion of the incident light. Reflection occurs when a ray of incoming light encounters a boundary or interface characterized by a change in refractive index between two media. For the top layer of the antimicrobial materials of this invention, that interface is with air. For the base layer, the interface is with the top layer. The reflectance of the base and top layers is balanced so as to generate an interference colour. [0065]
  • “Partly light transmissive” when used to describe a thin film of the top layer material means that the thin film is capable of transmitting at least a portion of incident visible light through the thin film. [0066]
  • “Detectable” when used to describe a colour change means an observable shift in the dominant wavelength of the reflected light, whether the change is detected by instrument, such as a spectrophotometer, or by the human eye. The dominant wavelength is the wavelength responsible for the colour being observed. [0067]
  • “Cold working” as used herein indicates that the material has been mechanically worked such as by milling, grinding, hammering, mortar and pestle or compressing, at temperatures lower than the recrystallization temperature of the material. This ensures that atomic disorder imparted through working is retained in the material. [0068]
  • “Pharmaceutically- or therapeutically-acceptable” is used herein to denote a substance which does not significantly interfere with the effectiveness or the biological activity of the active ingredients (pro-apoptotic and anti-MMP properties) and which has an acceptable toxic profile for the host to which it is administered. [0069]
  • “Therapeutically effective amount” is used herein to denote any amount of a formulation of the antimicrobial or noble metals which will exhibit either or both of a pro-apoptotic and anti-MMP effect, when applied to the affected area. A single application of the formulations of the present invention may be sufficient, or the formulations may be applied repeatedly over a period of time, such as several times a day for a period of days or weeks. The amount of the active ingredient, that is the antimicrobial or noble metal in the form of a coating, powder or dissolved in liquid solution, will vary with the conditions being treated, the stage of advancement of the condition, the age and type of host, and the type and concentration of the formulation being applied. Appropriate amounts in any given instance will be readily apparent to those skilled in the art or capable of determination by routine experimentation. [0070]
  • “Carrier” means a suitable vehicle including one or more solid, semisolid or liquid diluents, excipients or encapsulating substances which are suitable for administration to the area. [0071]
  • “Nanocrystalline” is used herein to denote single-phase or multi-phase polycrystals, the grain size of which is less than about 100, more preferably <50, even more preferably <40, even more preferably <30, and most preferably <25 nanometers in at least one dimension. The term, as applied to the crystallite or grain size in the crystal lattice of coatings, powders or flakes of the antimicrobial or noble metals, is not meant to restrict the particle size of the materials when used in a powder form. [0072]
  • “Powder” is used herein to include particulates of the antimicrobial or noble metals ranging from nanocrystalline (less than 100 nm) to submicron sized powders up to flakes. [0073]
  • Preferably, powders of the antimicrobial or noble metals used in the present invention are sized at less than 100 μm, and more preferably less than 40 μm, and most preferably less than 10 μm. [0074]
  • “Grain size”, or “crystallite size” means the size of the largest dimension of the crystals in the antimicrobial metal coating or powder. [0075]
  • “Hydrocolloid” means a synthetically prepared or naturally occurring polymer capable of forming a thickened gel in the presence of water and polyols (swelling agent). The swelling agent must be capable of swelling the hydrocolloid chosen in order to form the gel phase. [0076]
  • “Hydrogels” means a hydrocolloid swollen with water or another hydrophilic liquid which is used for absorbing or retaining moisture or water. [0077]
  • “Gel” means a composition that is of suitable viscosity for such purposes, e.g., a composition that is of a viscosity that enables it to be applied and remain on the skin. [0078]
  • When used herein and in the claims, the term “nanocrystalline antimicrobial metal” and similar terminology, such as “nanocrystalline coatings or powders” is meant to refer to antimicrobial metals formed with atomic disorder and having a nanocrystalline grain size.[0079]
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 is a graph showing MMP activity of incision fluids recovered from incisions dressed with silver-coated dressing (AB), silver nitrate moistened gauze (SN), silver-coated AgHDPE, and control dressing on each post-incision day. [0080]
  • FIG. 2 is a graph showing total protease activity of incision fluids recovered from the silver-coated dressing (AB), silver nitrate moistened gauze (SN dressing), silver-coated AgHDPE, and control dressing over a duration of 5 days. [0081]
  • DESCRIPTION OF THE PREFERRED EMBODIMENTS
  • Crystalline forms of the antimicrobial metals Ag, Au, Pt, and Pd can be prepared as coatings or powders, or as solutions prepared by dissolving the coatings or powders. The crystalline coatings or powders are most preferably formed with atomic disorder in accordance with the techniques published in the prior patent applications of Burrell et al, see for example WO 93/23092, published Nov. 25, 1993, WO 95/13704, published May 26, 1995 and WO 98/41095, published Sep. 24, 1998. [0082]
  • Pharmaceutical formulations for treatment of hyperplastic tissue, tumor tissue, or cancerous lesions utilize the antimicrobial or noble metals in powder, coatings or solution form. Preparation of the antimicrobial or noble metals as powders or coatings is set out below in section A, format for formulations are set forth in section B, sterilization in section C, and formulating, dosages and treatment are set forth in section D. [0083]
  • A. Preparation of Crystalline Forms of the Antimicrobial Metals with Atomic Disorder [0084]
  • a) Antimicrobial Metal Coatings on Dressings or Other Substrates [0085]
  • Dressings or other substrates such as packings, vials, fabric, or fibres etc. may be coated with antimicrobial coatings formed with atomic disorder. The description below is directed to coatings on dressing materials, but the coating techniques are equally applicable to coating other substrates. Dressings coated with antimicrobial metals in accordance with the invention include one or more layers of medical dressing materials. Multiple layers may be laminated together by known means such as low temperature thermal fusing, stitching or, most preferably, ultrasonic welding. [0086]
  • The dressing may be formed to include an occlusive or semi-occlusive layer such as an adhesive tape or polyurethane film in order to secure the dressing in place, and retain moisture for release of ions, atoms, molecules or clusters of the antimicrobial metal (hereinafter antimicrobial metal species). [0087]
  • The preferred and alternate compositions of the dressing layers, together with the preferred nanocrystalline antimicrobial metal coatings, are set out in further detail below. [0088]
  • i) Dressing Materials [0089]
  • The dressing is formed of a perforated, preferably non-adherent material which allows for fluids to penetrate or diffuse there through in either or both directions. The perforated material may be formed of a woven or non-woven, non-woven being preferred, fabric such as cotton, gauze, a polymeric net or mesh such as polyethylene, nylon, polypropylene or polyester, an elastomer such as polyurethane or polybutadiene elastomers, or a foam such as open cell polyurethane foam. Exemplary perforated, non-adherent materials useful for the dressing include non-woven meshes such as DELNET™ P530, which is a non-woven veil formed of high density polyethylene using extrusion, embossing and orientation processes, produced by Applied Extrusion Technologies, Inc. of Middletown, Del., USA. This same product is available as Exu-Dry CONFORMANT 2™ Wound Veil, from Frass Survival Systems, Inc., Bronx, N.Y., USA as a subset of that company's Wound Dressing Roll (Non-Adherent) products. Other useful non-woven meshes include CARELLE™ or NYLON 90™, available from Carolina Formed Fabrics Corp., N-TERFACE™, available from Winfield Laboratories, Inc., of Richardson, Tex., USA. Exemplary woven meshes may be formed from fibreglass or acetate, or cotton gauze. An exemplary hydrophilic polyurethane foam is HYPOL™, available from W.R. Grace & Co., New York, N.Y., USA. [0090]
  • For ease of ultrasonic welding for lamination, at least one dressing layer is preferably formed from a polymeric material which is amenable to ultrasonic welding, that is which will melt on the application of localized heat and then fuse multiple layers together on cooling. [0091]
  • If desired, a second, absorbent layer is formed from an absorbent material for holding sufficient moisture next to the affected area in order to activate the antimicrobial metal coating, that is to cause release of ions, molecules, atoms or clusters of the antimicrobial metal in order to cause pro-apoptotic and anti-MMP effects. Preferably, the absorbent material is an absorbent needle punched non-woven rayon/polyester core such as SONTARA™ 8411, a 70/30 rayon/polyester blend commercially available from Dupont Canada, Mississauga, Ontario, Canada. This product is sold by National Patent Medical as an American White Cross sterile gauze pad. However, other suitable absorbent materials include woven or non-woven materials, non-woven being preferred made from fibers such as rayon, polyester, rayon/polyester, polyester/cotton, cotton and cellulosic fibers. Exemplary are creped cellulose wadding, an air felt of air laid pulp fibers, cotton, gauze, and other well known absorbent materials suitable for medical dressings. [0092]
  • A third layer of the dressing, if used, is preferably formed of perforated, non-adherent material such as used in the first layer. This allows moisture penetration as sterile water and the like are added in order to activate the antimicrobial metal coating. [0093]
  • Additional layers may be included between or above the first, second and third layers as is well known in medical dressings. The coated dressing layers may be combined with an adhesive layer, in a well known manner. [0094]
  • The dressing may be used as a single layer, or may be used as multiple layers laminated together at intermittent spaced locations across the dressing by ultrasonic welds. Ultrasonic welding is a known technique in the quilting art. Briefly, heat (generated ultrasonically) and pressure are applied to either side of the dressing at localized spots through an ultrasonic horn so as to cause flowing of at least one of the plastic materials in the first and second layers and the subsequent bonding together of the layers on cooling. The welds appear at localized circular spots and are preferably less than 0.5 cm in diameter. [0095]
  • The use of ultrasonic welding of the layers at spaced locations has the advantage of retaining the absorbent and moisture penetration properties of the dressing layers, while retaining the conforming properties of the dressing. Edge seams, stitching and adhesives have the disadvantage of interfering with one or more of these desirable properties of the dressings. Furthermore, by spacing the welds at intermittent locations across the dressing, the dressing may be cut to smaller sizes, as needed, without causing delamination. Preferred spacings of about 2.5 cm between welds allows the dressing to be cut down to about 2.5 cm sizes, while maintaining at least one weld to hold the laminated layers together. [0096]
  • ii) Nanocrystalline Coatings of Antimicrobial Metals [0097]
  • The coated substrate, for example a dressing, preferably includes a nanocrystalline coating of one or more of the antimicrobial metals. The coating is applied to one or more of the dressing layers, but is most preferably applied at least to the skin facing layer. [0098]
  • The nanocrystalline coating is most preferably formed with atomic disorder in accordance with the procedures set out above and as described in WO 93/23092, WO 95/13704, and WO98/41095, and as set out below. Most preferably, the coating is formed as a multilayer coating of the antimicrobial metals, having a top and a base layer, as set below, to produce an interference colour. In this way, the coating provides not only the active ingredient for treatment of hyperplastic tissue, tumor tissue, or a cancerous lesion, but also acts as an indicator of activation of the dressing. As the top layer of the coating is activated with an alcohol or water-based electrolyte, such as sterile water or ethanol, even minor dissolution of the antimicrobial metal results in a detectable colour change, indicating that the coating has been activated. If there is no colour change, additional moisture might be provided to the dressing by adding water, until a colour change is detected. Once activated, the dressing should be maintained in a moist condition, for example by the addition of sterile water, if necessary. [0099]
  • iii) Multilayer Nanocrystalline Coatings of Antimicrobial Metals With Interference Colour [0100]
  • The coated substrates, for example dressings may include the antimicrobial metal coating formed with at least two metal layers, a base layer and a top layer over the base layer, so as to produce an interference colour, as set forth in WO 98/41095, the teachings of which are incorporated herewith by reference. The indicator colour can function as an indicator when contacted with a water or alcohol based electrolyte, since the coating will change colour. An exemplary multilayer nanocrystalline coating of silver with a blue interference colour is set forth in Example 1. [0101]
  • iv) Nanocrystalline Coatings of Antimicrobial Metals Containing Atomic Disorder [0102]
  • The coatings of the present invention are formed in a crystalline form from one or more antimicrobial metals with atomic disorder. The production of atomic disorder through physical vapour deposition techniques is described in WO 93/23092 and WO 95/13704, and as outlined below. [0103]
  • The antimicrobial metal is deposited as a thin metallic film on one or more surfaces of the dressing by vapour deposition techniques. Physical vapour techniques, which are well known in the art, all deposit the metal from the vapour, generally atom by atom, onto a substrate surface. The techniques include vacuum or arc evaporation, sputtering, magnetron sputtering and ion plating. The deposition is conducted in a manner to create atomic disorder in the coating as defined above. Various conditions responsible for producing atomic disorder are useful. These conditions are generally those which one has been taught to avoid in thin film deposition techniques, since the object of most thin film depositions is to create a defect free, smooth and dense film (see for example J. A. Thornton, “Influence of Apparatus Geometry and Deposition Conditions on the Structure and Topography of Thick Sputtered Coatings,” J. Vac. Sci. Technol., 11(4), 666-670, 1974). [0104]
  • The preferred conditions which are used to create atomic disorder during the deposition process include: [0105]
  • a low substrate temperature, that is maintaining the surface to be coated at a temperature such that the ratio of the substrate temperature to the melting point of the metal (in degrees Kelvin) is less than about 0.5, more preferably less than about 0.35 and most preferably less than about 0.3; and optionally one or both of: [0106]
  • a higher than normal working gas pressure (or ambient pressure in depositions not using a working gas), i.e. for vacuum evaporation: e-beam or arc evaporation, greater than 0.001 Pa (0.01 mT), gas scattering evaporation (pressure plating) or reactive arc evaporation, greater than 2.67 Pa (20 mT); for sputtering: greater than 10 Pa (75 mT); for magnetron sputtering: greater than about 1.33 Pa (10 mT); and for ion plating: greater than about 26.67 Pa (200 mT); and [0107]
  • maintaining the angle of incidence of the coating flux on the surface to be coated at less than about 750, and preferably less than about 30°. [0108]
  • For economic reasons, the thin metal film has a thickness no greater than that needed to provide release of antimicrobial metal species on a sustainable basis over a suitable period of time, and to generate the desired interference colour. Within the preferred ranges of thicknesses set out above, the thickness will vary with the particular metal in the coating (which varies the solubility and abrasion resistance), and with the degree of atomic disorder in (and thus the solubility of) the coating. The thickness will be thin enough that the coating does not interfere with the dimensional tolerances or flexibility of the device for its intended utility. [0109]
  • The therapeutic effect of the material so produced is achieved when the coating is brought into contact with an alcohol or a water based electrolyte, thus releasing metal ions, atoms, molecules or clusters. The concentration of the metal species which is needed to produce a therapeutic effect will vary from metal to metal. [0110]
  • The ability to achieve release of metal atoms, ions, molecules or clusters on a sustainable basis from a coating is dictated by a number of factors, including coating characteristics such as composition, structure, solubility and thickness, and the nature of the environment in which the device is used. As the level of atomic disorder is increased, the amount of metal species released per unit time increases. For instance, a silver metal film deposited by magnetron sputtering at T/Tm<0.5 and a working gas pressure of about 0.93 Pa (7 mT) releases approximately 1/3 of the silver ions that a film deposited under similar conditions, but at 4 Pa (30 mT), will release over 10 days. Films that are created with an intermediate structure (ex. lower pressure, lower angle of incidence etc.) have Ag release values intermediate to these values as determined by bioassays. This then provides a method for producing controlled release metallic coatings. Slow release coatings are prepared such that the degree of disorder is low while fast release coatings are prepared such that the degree of disorder is high. [0111]
  • For continuous, uniform coatings, the time required for total dissolution will be a function of film thickness and the nature of the environment to which they are exposed. The relationship in respect of thickness is approximately linear, i.e. a two fold increase in film thickness will result in about a two fold increase in longevity. [0112]
  • It is also possible to control the metal release from a coating by forming a thin film coating with a modulated structure. For instance, a coating deposited by magnetron sputtering such that the working gas pressure was low (ex. 2 Pa or 15 mT) for 50% of the deposition time and high (ex. 4 Pa or 30 mTorr) for the remaining time, has a rapid initial release of metal ions, followed by a longer period of slow release. This type of coating is extremely effective on devices such as urinary catheters for which an initial rapid release is required to achieve immediate antimicrobial concentrations followed by a lower release rate to sustain the concentration of metal ions over a period of weeks. [0113]
  • The substrate temperature used during vapour deposition should not be so low that annealing or recrystallization of the coating takes place as the coating warms to ambient temperatures or the temperatures at which it is to be used (ex. body temperature). This allowable ΔT, that the temperature differential between the substrate temperature during deposition and the ultimate temperature of use, will vary from metal to metal. For the most preferred metal, Ag, preferred substrate temperatures of −20 to 200° C. , more preferably −10° C. to 100° C. are used. [0114]
  • Atomic order may also be achieved, in either or both of the base and top layers by preparing composite metal materials, that is materials which contain one or more antimicrobial metals in a metal matrix which includes atoms or molecules different from the antimicrobial metals. [0115]
  • The preferred technique for preparing a composite material is to co- or sequentially deposit the antimicrobial metal(s) with one or more other inert, biocompatible metals selected from Ta, Ti, Nb, Zn, V, Hf, Mo, Si, Al and alloys of these metals or other metal elements, typically other transition metals. Such inert metals have a different atomic radii from that of the antimicrobial metals, which results in atomic disorder during deposition. Alloys of this kind can also serve to reduce atomic diffusion and thus stabilize the disordered structure. Thin film deposition equipment with multiple targets for the placement of each of the antimicrobial and biocompatible metals is preferably utilized. When layers are sequentially deposited the layer(s) of the biocompatible metal(s) should be discontinuous, for example as islands within the antimicrobial metal matrix. The final weight ratio of the antimicrobial metal(s) to biocompatible metal(s) should be greater than about 0.2. The most preferable biocompatible metals are Ti, Ta, Zn and Nb. It is also possible to form the antimicrobial coating from oxides, carbides, nitrides, sulphides, borides, halides or hydrides of one or more of the antimicrobial metals and/or one or more of the biocompatible metals to achieve the desired atomic disorder. [0116]
  • Another composite material may be formed by reactively co- or sequentially depositing, by physical vapour techniques, a reacted material into the thin film of the antimicrobial metal(s). The reacted material is an oxide, nitride, carbide, boride, sulphide, hydride or halide of the antimicrobial and/or biocompatible metal, formed in situ by injecting the appropriate reactants, or gases containing same, (ex. air, oxygen, water, nitrogen, hydrogen, boron, sulphur, halogens) into the deposition chamber. Atoms or molecules of these gases may also become absorbed or trapped in the metal film to create atomic disorder. The reactant may be continuously supplied during deposition for codeposition or it may be pulsed to provide for sequential deposition. The final weight ratio of reaction product to antimicrobial metal(s) should be greater than about 0.05. Air, oxygen, nitrogen and hydrogen are particularly preferred reactants, with oxygen being most preferred. [0117]
  • The above deposition techniques to prepare composite coatings may be used with or without the conditions of lower substrate temperatures, high working gas pressures and low angles of incidence previously discussed. One or more of these conditions are preferred to retain and enhance the amount of atomic disorder created in the coating. [0118]
  • The most preferred composite coatings are formed by sputtering silver, under conditions set out above, in an atmosphere containing oxygen, so as to form a coating of silver as a composite coating with oxygen. [0119]
  • Dressings coated with the antimicrobial coatings of this invention may be sterilized in the manner set out below. [0120]
  • b) Powders of Atomically Disordered Antimicrobial Metals [0121]
  • Crystalline powder forms of the antimicrobial or noble metals (particularly preferred being Ag, Au, Pt, and Pd) can be prepared as free standing powders, by coating powdered substrates, or from coatings on substrates which are then collected, for example by scaping and then sized. The powders may be prepared as pure metals, metal alloys or compounds such as metal oxides or metal salts, by vapour deposition, mechanical working, or compressing to impart the atomic disorder. The crystalline powders are formed with atomic disorder in accordance with the techniques set out above and as published in the prior patent applications of Burrell et al., see for example WO 93/23092, published Nov. 25, 1993, and WO 95/13704, published May 26, 1995. The atomic disorder will most typically be formed in the metal powders during physical vapour deposition as set out above for coatings or by mechanically imparting the disorder, such as by milling, grinding, hammering, mortar and pestle or compressing, under conditions of low temperature (i.e., temperatures less than the temperature of recrystallization of the material) to ensure that annealing or recyrstallization does not take place. [0122]
  • Alternatively, the powders may be formed by inert-gas condensation techniques, which are modified to provide atomic disorder in the powder produced, as taught in WO 95/13704 to Burrell et al. [0123]
  • Powders of the antimicrobial or noble metals are preferably formed by physical vapour deposition (PVD) onto a substrate such as a cold finger, a silicon wafer, solid plates, a rotating cylinder, a continuous belt in a roll coater, or on steel collectors in known PVD coaters. Preparation of powders of the present invention by sputtering onto a continuous belt in a roll coater, or other some other moving or rotating substrate surface is particularly advantageous, inasmuch as it can quickly and easily yield a relatively large supply of free-standing powder at a relatively low cost. A stainless steel belt can be used in the roll coating process without the need to provide additional cooling of the substrate. The powders or coatings and then are then scraped off to form a powder, and may be sized to avoid overly large particulates. The powders are scraped off the moving surface with scrapers which contact the moving surface at an angle sufficient to remove the coating in flake or powder form. The coating may be scraped off with scrapers angled for forward cutting of the coating from the moving surface, or with scrapers which remove the coating from the moving surface by reverse dragging action on the surface. The scrapers may be suspended above the belt, and either weighted or spring loaded to apply pressure sufficient to remove the coating from the moving surface. With a continuous belt, the scrapers can conveniently be located above the end rollers to remove the coating with a reverse dragging action as the belt rounds the end roller. [0124]
  • Alternatively, the powders of the antimicrobial or noble metals may be formed on powdered substrates which are biocompatible, or otherwise compatible for the end use of the powder. Particularly preferred powdered substrates are hydrocolloids, particularly those which are bioabsorbable and/or hygroscopic powders such as chitin. Exemplary bioabsorbable and/or hygroscopic powders are composed of: [0125]
  • Synthetic Bioabsorbable Polymers: for example polyesters/polyactones such as polymers of polyglycolic acid, glycolide, lactic acid, lactide, dioxanone, trimethylene carbonate etc., polyanhydrides, polyesteramides, polyortheoesters, polyphosphazenes, and copolymers of these and related polymers or monomers. [0126]
  • Naturally Derived Polymers: [0127]
  • Proteins: albumin, fibrin, collagen, elastin; [0128]
  • Polysaccharides: chitosan, alginates, hyaluronic acid; and [0129]
  • Biosynthetic Polyesters: 3-hydroxybutyrate polymers. [0130]
  • The powders may be incorporated into or onto medical dressings or pharmaceutical formulations, by any methods known in the art. For example, the powders may be layered onto the substrates (dressings or powders), mechanically fixed within the fibres of the dressings, impregnated into dressings by physical blowing, or added to topical pharmaceutical ingredients. [0131]
  • Preferably, powders of the present invention are sized at less than 100 μm, and more preferably less than 40 μm, and most preferably about 3-5 μm in size. For direct application to a locus of the hyperplastic tissue, tumor tissue, or a cancerous lesion, powders are preferably sized less than 2 μm, and more preferably less than 1 μm. [0132]
  • B. Formulations for Administration [0133]
  • 1. Coated substrates coated with antimicrobial metals formed with atomic disorder are well described above. These techniques can be used to coat dressings, meshes, films, filtering surfaces, filters, packing fibres, the insides of vials or containers etc. The coated substrates in the form of dressings for example, can be used directly on the affected area, or they can be used to generate powders, liquid or other formulations as set out below. [0134]
  • 2. Powders of the antimicrobial metals formed with atomic disorder are set out above, and may be used in that form directly on the affected area, or in other formulations such as dressings, occlusions, creams, liquids etc. Alternatively, powders may be formulated within liquid pervious membranes such as filters, meshes and the like, such as a tea bag-type infuser, for generating liquids containing dissolved species of the antimicrobial metal. [0135]
  • 3. Occlusions may include a hydrated dressing, with a sealing material overlaid on the outside, to the area, e.g. skin cancer, to be treated. The term hydrated dressing is meant to include non-hydrated dressings which become hydrated upon contact with an alcohol or water-based electrolyte. Occlusion prevents loss of the therapeutic agent from the area, promotes hydration of the area, and increases the temperature of the area. Examples of hydrated dressings include hydrocolloids, hydrogels, polyethylene, polyurethane, polyvinylidine, and siloxane or silicone dressings. The hydrated dressing can either be impregnated with a solution or powder of the antimicrobial metals of this invention, or can be used with a topical formulation of the antimicrobial metals of this invention. [0136]
  • An exemplary occlusion is a hydrocolloid dressing impregnated with silver. Alternatively, one might use a non-impregnated hydrocolloid dressing to occlude nanocrystalline silver-containing gel placed on a problematic area. A hydrocolloid is a synthetically prepared or naturally occurring polymer capable of forming a thickened gel in the presence of water and polyols (swelling agent). The swelling agent is a hydrophilic liquid capable of swelling the hydrocolloid chosen in order to form the gel phase. The hydrocolloid may be selected from the group comprising: [0137]
  • i representative natural or synthetically modified polysaccharides (e.g., cellulose or its derivatives such as carboxymethylcellulose, hydroxypropylcellulose, methylcellulose, hydroxypropylmethylcellulose or hydroxyethylcellulose, starch, glycogen, gelatin, pectin, chitosan and chitin; and [0138]
  • ii representative gums from algal extracts, seed extracts, or plant exudates (e.g., gum arabic, locust bean gum, karaya gum, gum tragacanth, ghatti gum, agar-agar, carrageenans, alginates, carob gum, guar gum, xanthan gum); and [0139]
  • iii synthetic polymers which may be either linear or crosslinked (e.g. polymers prepared from N-vinyl lactams, e.g. N-vinyl-2-pyrrolidone, 5-methyl-N-vinyl-2-pyrrolidone). [0140]
  • The hydrocolloid is present in an amount of from about 0.1% to 20% of the weight and preferably 1% to 10%. The hydrocolloid can range for example, from 1 to 10% of the total weight of the composition. Alternatively, the hydrocolloid may be in the form of a powder whose average particle size is less than 100 μm preferably less than 50 μm. [0141]
  • The swelling agent should be non-volatile, and allow the gel to remain as a gel during use, hence preserving the swollen condition of the hydrocolloid. Varieties of non-volatile swelling agents include room temperature liquid polyols (including polyhydric alcohols) such as glycerol; room temperature solid polyols (including polyhydric alcohols) such as sorbitol, erythritol, threitol, ribotol, arabinitol, xylitol, allitol, talitol, mannitol, glucitol, glactitol, iditol, pentaerythritol, heptitol, octitol, nonitol, decitol, and dodecitol, blended with a room temperature liquid polyol; monoanhydroalditols (such as styracitol, polyalitol, D-fructose, 1,4 anhydro-D-mannitol and 1,4 anhydro-D-glucitol) blended with a room temperature liquid polyol; monosaccharides (such as pentoses, hexoses, and heptoses) blended with a room temperature liquid polyol; and ether alcohols blended with a room temperature liquid polyol. [0142]
  • Hydrocolloid dressings often comprise a wafer constructed from a thin layer of polyurethane film with an adhesive contact layer containing a hydrocolloid composition and securing the dressing to the area, and the polyurethane film being impermeable to water and microorganisms. Hydrocolloid dressings may be prepared by dispersing a composition in gel form of hydrocolloids with a swelling agent into a strong pressure sensitive adhesive. Alternatively, the gel and the adhesive may be mixed in a latex solution. Alternatively, exemplary products are available commercially, for example DuoDERM™ (ConvaTec Canada, 555, Dr. Frederik Philips, Suite 110, St-Laurent, Quebec, H4M 2×4); and Tegasorb™ (3M Health Care, 300 Tartan Drive, London, Ontario, Canada, N5V 4M9). The hydrocolloid dressing may be impregnated with a solution or powder of the antimicrobial metal by blending the solution or powder of the antimicrobial metal into a liquid phase during the manufacture of the hydrocolloid dressing, or by sprinkling and then pressing a powder of the antimicrobial metal into the surface of the hydrocolloid dressing. Further, the hydrocolloid dressing can be used with a topical formulation of the antimicrobial metals of this invention. Upon application, the dressing surface gels upon continued contact with moisture or exudate from the area, e.g. skin. With the incorporation of an antimicrobial metal such as silver (0.01-10%, preferably 0.1-1% by weight), the dressing is advantageous in being impermeable to water and microorganisms, and presenting antimicrobial and anti-inflammatory effects as mediated by the antimicrobial metal. [0143]
  • 4. Gels—Nanocrystalline gels may be formed from the nanocrystalline metal powder in admixture with gelling agents such as hydrocolloids and hydrogels in powder form. Exemplary gelling agents include carboxymethyl cellulose (CMC), polyvinyl alcohol (PVA), collagen, pectin, gelatin, agarose, chitin, chitosan, and alginate, with the gelling agent comprising between about 0.01-20% w/v. [0144]
  • 5. Creams Lotions, Pastes, Ointments, Foams—The antimicrobial metals may be incorporated into creams, lotions, pastes, ointments or foams formulated with nanocrystalline powders or solutions of the antimicrobial metals, for example as emulsions or with drying emollients. Ointments and creams can be formulated with an aqueous or oily base with the addition of suitable thickening and/or gelling agents. Such bases may include water and/or an oil such as liquid paraffin or a vegetable oil such as peanut oil or castor oil. An exemplary base is water. Thickening agents which can be used according to the nature of the base include aluminum stearate, hydrogenated lanolin, and the like. Further, lotions can be formulated with an aqueous base and will, in general, also include one or more of the following: stabilizing agents, emulsifying agents, dispersing agents, suspending agents, thickening agents, coloring agents, perfumes, and the like. Ointments and creams can also contain excipients, such as starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, and talc, or mixtures thereof. Lotions may be formulated with an aqueous or oily base and will, in general, also include one or more of the following: stabilizing agents, emulsifying agents, dispersing agents, suspending agents, thickening agents, coloring agents, perfumes, and the like. Foams may be formed with known foaming or surface active agents. [0145]
  • 6. Liquids—The crystalline forms of the antimicrobial metals may be incorporated into liquids, formulated as solutions, dispersion or suspensions by dissolving nanocrystalline coatings or powders of the antimicrobial metals, for example as topical solutions, aerosols, mists, sprays, drops, and instillation solutions for body cavities such as the bladder, prostate, lung, or liver. Topical administration of the antimicrobial metal to the skin may be performed by aerosol, which can be generated by a nebulizer, or by instillation. The antimicrobial metal may be administered alone, or with a carrier such as saline solution, an alcohol, water, or DMSO. An effective daily amount of the antimicrobial metal will vary with the subject, but will be less than is toxic while still providing a therapeutic effect. [0146]
  • Solutions and formulations of the antimicrobial metals may lose some activity with aging and are thus either stabilized or generated fresh for administration. Alternatively, the antimicrobial metals may be packaged for convenient solution generation, for instance as tea bag type infusers. Other two part or two phase systems may be used in which the nanocrystalline metal is separated from the water or alcohol-based electrolyte, for example in a multicomponent kit form, as set out herein. [0147]
  • Concentrations of the antimicrobial metal species in solution will vary according to the application, formulation and subject, but will generally range from 1-5000 μg/ml, more preferably 20-3000,g/ml, more preferably 40-800 μg/ml, and most preferably 50-500 μg/ml. Methods of generating liquids with appropriate concentrations of the antimicrobial metal through pH control are set out below. [0148]
  • 7. Transdermal Patch [0149]
  • Transdermal patches may provide controlled delivery of the antimicrobial metal to the area. For example, an adhesive patch or adhesive matrix patch, can be prepared from a backing material and an adhesive, such as an acrylate adhesive. Powders or solutions of the antimicrobial metal may be formulated into the adhesive casting solution and allowed to mix thoroughly. The solution is cast directly onto the backing material and the casting solvent is evaporated in an oven, leaving an adhesive film. Alternatively, a polyurethane matrix patch can be employed to deliver the antimicrobial metal to the area. The layers of this patch comprise a backing, a polyurethane drug/enhancer matrix, a membrane, an adhesive, and a release liner. The polyurethane matrix is prepared using a room temperature curing polyurethane prepolymer. Addition of water, alcohol, and drug to the prepolymer results in the formation of a tacky firm elastomer that can be directly cast onto the backing material. [0150]
  • C. Sterilization [0151]
  • Dressings with nanocrystalline coatings of a antimicrobial metal formed with atomic disorder are preferably sterilized without applying excessive thermal energy, which can anneal out the atomic disorder, thereby reducing or eliminating a useful release of antimicrobial metal species. Gamma radiation is preferred for sterilizing such dressings, as discussed in WO 95/13704. Electron beam and ethylene oxide sterilization techniques can also be used. [0152]
  • It should be appreciated that the use of ultrasonic welding to laminate the layers of dressings with nanocrystalline coatings formed from antimicrobial metals with atomic disorder is advantageous since it achieves bonding in localized spots and avoids applying heat to any significant portion of the dressing, thereby avoiding any significant reduction in the solubility of the antimicrobial metals through annealing out of the atomic disorder. [0153]
  • The sterilized dressings, coating, powders or formulations should be sealed in packaging, containers, or kits which limit moisture and light penetration to avoid additional oxidation or reduction of the antimicrobial metal. Polyester peelable pouches are preferred. The shelf life of coatings or powders thus sealed is over one year. [0154]
  • D. Formulating Dosages and Treatment [0155]
  • Typically, the nanocrystalline antimicrobial metals will be formulated from the active ingredient, namely nanocrystalline powders or coatings of the antimicrobial metals, or dissolved species from such powders or coatings, in the one or more of the formats set out above. Dressing or powders of the nanocrystalline antimicrobial metals may be applied directly to the hyperplastic tissue, tumor tissue, or cancerous lesion, or they may be formulated as set out below. Depending on the particular application and dosage form, the powder size might be controlled to less than 2 μm, more preferably to less than 1 μm. [0156]
  • In the pharmaceutical compositions, the amount of the nanocrystalline metal powder may range broadly from about 0.001% to about 30% by weight, but will more preferably fall in the range of from about 0.01 to 10% by weight, and most preferably in the range of about 0.1 to 5% by weight. Typical coating thicknesses are in the range of 150 to 3000 nm thick. Thicker coatings, up to 10,000 nm thick, can be used to generate powders of the antimicrobial metal. Coatings of the nanocrystalline antimicrobial metals may be very thin, or thick, depending on the desired duration of application on the patient. As liquid formulations, the amount of dissolved antimicrobial metal will typically range between about 0.001 to 10% by weight, more preferably 0.01 to 1% by weight. [0157]
  • Besides the active ingredient, pharmaceutical compositions may also include non-toxic, pharmaceutically acceptable carriers, diluents and excipients, suitable for topical application, as are well known, see for example Merck Index, Merck & Co., Rahway, N.J.; and Gilman et al., (eds) (1996) Goodman and Gilman's: The Pharmacological Bases of Therapeutics, 8[0158] th Ed., Pergamon Press. For standard dosages of conventional pharmacological agents, see, e.g., Physicians Desk Reference (1997 Edition); and U.S. Pharmacopeia National Formulary (1995) United States Pharmacopeial Convention Inc., Rockville, Md.
  • Dosage forms for the topical administration of compositions of the nanocrystalline antimicrobial metals include various mixtures and combinations that can be applied topically and will permit even spreading and absorption into the cutaneous surfaces. Examples include sprays, mists, aerosols, lotions, creams, solutions, gels, ointments, pastes, emulsions, foams and suspensions. The active compound can be mixed under sterile conditions with a pharmaceutically acceptable carrier, and with any preservatives, buffers, or propellants which may be required. Topical preparations can be prepared by combining the antimicrobial metal powder with conventional pharmaceutically acceptable carriers commonly used in topical dry, liquid, cream and aerosol formulations. Ointment and creams can, for example, be formulated with an aqueous or oily base with the addition of suitable thickening and/or gelling agents. An exemplary base is water. Thickening agents can be used according to the nature of the base. Lotions can be formulated with an aqueous base and will, in general, also include one or more of the following: stabilizing agents, emulsifying agents, dispersing agents, suspending agents, thickening agents, coloring agents, perfumes, and the like. Powders can be formed with the aid of any suitable powder base, e.g., talc, lactose starch and the like. Drops can be formulated with an aqueous base or non-aqueous base, and can also include one or more dispersing agents, suspending agents, solubilizing agents, surface active agents and the like. [0159]
  • Ointments, pastes, creams and gels also can contain excipients, such as starch, tragacanth, cellulose derivatives, silicones, bentonites, silicic acid, and talc, or mixtures thereof. Powders and sprays also can contain excipients such as lactose, talc, silicic acid, aluminum hydroxide, and calcium silicates, or mixtures of these substances. Solutions of nanocrystalline antimicrobial metals can be converted into aerosols or sprays by any of the known means routinely used for making aerosol pharmaceuticals. In general, such methods comprise pressurizing or providing a means for pressurizing a container of the solution, usually with an inert carrier gas, and passing the pressurized gas through a small orifice. Sprays can additionally contain customary propellants, such as inert gases such as nitrogen, carbon dioxide, argon or neon. [0160]
  • Multiple inactive ingredients are generally incorporated in topical formulations to improve cosmetic acceptability, and are optional ingredients in the formulations. Such ingredients are included only in therapeutically acceptable forms and amounts. Examples of ingredients are emulsifiers, emollients, thickening agents, solvents, hydrating or swelling agents, flavours, sweetening agents, surface active agents, colouring agents, anti-foaming agents, preservatives, fragrances, and fillers may also be added, as is well known in the art; for example, preservatives such as methyl paraben and propyl paraben, texturizing agents, thickeners, anticoagulants such as heparin, β-glucan, hormones, hyaluronic acid, and the like. Polyvinyl alcohol is a particularly preferred gelling polymer and also acts as a texturizing agent, methyl or propyl parabens are particularly preferred preservatives. These other agents may be included in amounts in the range of 0.1 to 5 wt %. [0161]
  • Surface active agents or foaming agents may be added to the formulations and are particularly advantageous for addition to liquid formulations for aerosol or foam applications, to form foams for applications such as to treat cancerous lesions on the skin, or aerosols for application for respiratory disorders. Surface active agents selected for use should not substantially interfere with the pro-apoptotic and anti-MMP effects of the nanocrystalline antimicrobial metals. [0162]
  • All agents must be non-toxic and physiologically acceptable for the intended purpose, and must not substantially interfere with the activity of the nanocrystalline antimicrobial metals so as to deleteriously affect the pro-apoptotic and anti-MMP effects. Ingredients are thus only included in therapeutically acceptable amounts. Ingredients to be generally avoided or limited in the formulations of the present invention, at least in amounts greater than 0.01 wt %, are glycerin, glycerols, chloride salts, aldehydes, ketones, long chain alcohols, and triethanolamine. [0163]
  • The dosage of the active ingredients depends upon many factors that are well known to those skilled in the art, for example, the particular form of the active ingredient, the condition being treated, the age, weight, and clinical condition of the recipient patient, and the experience and judgement of the clinician or practitioner administering the therapy. A therapeutically effective amount of the nanocrystalline antimicrobial metal provides either subjective relief of symptoms or an objectively identifiable improvement as noted by the clinician or other qualified observer. The dosing range varies with the metal used, its form, the route of administration and the potency of the particular compound. [0164]
  • When the formulation is in the form of a dressing, the dressing is placed on the afffected area (e.g, cancerous lesion on the skin) and, depending on the degree of moisture at the membrane, may be further moistened with drops of sterile water, tap water, body fluids such as exudate or, for example 70% ethanol, in order to activate the coating for release of antimicrobial or noble metal species. The dressing may be then secured in place with an occlusive or semi-occlusive layer, such as an adhesive tape or polyurethane film, which keeps the dressing in a moist environment. In use, the dressings are kept moist, at 100% relative humidity. Adding sterile water initially to activate the antimicrobial or noble metal coating is needed, and then as needed to maintain the dressing in a moist condition. Dressings may be changed as required for observation and cleaning. Preferably dressings are changed daily, but could be left longer, such as 3 days, and can provide a therapeutic effect for a much longer period of time. [0165]
  • Other forms of formulations, such as occlusions, gels, pastes, ointments, creams, emulsions, foams, and liquids may be prepared in stable forms, or more preferably are prepared fresh from one or more phases, for instance in multicomponent kit form, so as to avoid aging and to maximize the therapeutic effectiveness of the antimicrobial metal component. Formulations are best used within about 30 days after combining the phases. Suitable kits or containers are well known for maintaining the phases of formulations separate until the time of use. For instance, the antimicrobial metal in powder or coated substrate form may be packages separately from therapeutically acceptable carriers, and possibly other ingredients for mixing at the time of use. The separate coated substrate may be in dressing or patch form for direct application, or may take other suitable forms to generate liquid formulations and the like, such as a coating on the inside surface of a vial or container, a mesh, or a film. For example, the antimicrobial metal may be provided in a “tea bag”-type infuser or pouch, for generating liquid formulations at the time of use. The tea bag-type infuser is advantageous in that the pouch may serve as a filter for small particulates of the powder that may be detrimental to administration for some applications such as aerosols for respiratory disorders. A kit containing the dressing, coated substrate or powder may provide a sterile carrier such as water (and other ingredients) in a separate container in dosage specific amounts. As used herein, the term “kit” is meant to refer to packaged formulations, whether the ingredients are in separate phases or mixed, and thus for example, may include a gel in a tube with all ingredients in admixture, or any formulation wherein the ingredients are separated from each other. [0166]
  • Formulations for respiratory disorders may be delivered as dry powders in dry powder inhalers, or they may be formulated in liquid formulations for delivery in metered dose inhalers, aerosols, mists or sprays. [0167]
  • For liquid formulations, in order to increase the amount of antimicrobial or noble metal solubilized in the solution, the pH of the solution during dissolution may be lowered to less than pH 6.5, more preferably to the range of 3.5 to 6.5, with such acidifying agents as carbon dioxide (which generated carbonic acid in solution). This pH range will typically generate concentrations of silver from atomic disordered silver from 85 μg/ml to 370 μg/ml, and can be adjusted for different desired concentrations. Dissolution of the antimicrobial metal will typically raise the pH to 6.5 to 7.0. [0168]
  • Administration as aerosols produces droplets preferably less than 10 μm in size, more preferably less than 5 μm in size, most preferably 1-3 μm in size. Control of the droplet size is important both to control the dosage delivered and to enhance delivery to the target tissues, e.g., where the aerosol is inhaled through the mouth, large droplets of about 10 μm tend to stay in the throat whereas small droplets (e.g., approximately 1-3 μm) tend to travel to the aveolar region of the lungs. Thus, depending on the dosage required and the target tissue, it may be important to regulate the droplet size of the aerosol. In this respect, it has been found that droplet size can be regulated, to at least some extent, by the mechanical mister which is used to produce the aerosol. In addition, the aerosol's droplet size can be adjusted, to at least some extent, by modifying the surface tension of the solution. More particularly, the solution of the antimicrobial metal typically has water as its solvent, and water has a relatively high surface tension, so it is relatively straightforward to create an aerosol having relatively small droplet size. Surface active agents can be added to the solution so as to reduce the surface tension of the solution, to create an aerosol having a relatively large droplet size. By way of example, such surfactants may comprise sodium alkyl sulfates, sodium lauryl sulfate, sodium lauroyl sarconsinate, phospholipids, e.g., lecithin, sphingomyelin, etc. [0169]
  • Depending on the application, solutions generated from powders of the antimicrobial metal should avoid inclusion of particulates larger than 2 μm, and more preferably no larger than 1 μm (i.e., submicron) to avoid deleterious immune responses or toxic effects. Larger particulates may be removed by, for example filtration. Particulates may be formed in the liquid and can be removed, for example by filtration. For instance, silver carbonates may be formed on reaction with the carbonic acid used to acidify the solution. Particulate generation may also be limited by diluting the carbonic acid in solution. [0170]
  • The aerosol may be created by passing a liquid solution of the antimicrobial metal through a mechanical mister (e.g., a nebulizer) and may be applied directly with a pressurized pack (e.g., via a hand inhaler with a propellant such as carbon dioxide or other gas, with a valve metered dosage) or through some other delivery system (e.g., an oxygen tent, etc.). [0171]
  • The invention provides methods of treatment, by administering a therapeutically effective amount of a nanocrystalline antimicrobial or noble metal powder, or a solution derived from a nanocrystalline antimicrobial or noble metal, as either a topical formulation, or as a coating on medical dressing, applied to the locally affected area, e.g. hyperplastic tissue, tumor tissue, or cancerous lesion. A therapeutically effective amount may be determined by testing formulations containing the nanocrystalline antimicrobial or noble metals by in vitro or in vivo testing. Formulations may be applied one or more times a day. Dressings coated with the nanocrystalline antimicrobial or noble metals may be changed daily, or even less frequently, and should be kept in a moist condition with the addition of saline, alcohols, or more preferably sterile water, in order to release ions, atoms, molecules or clusters of the nanocrystalline metal, on a sustained basis. [0172]
  • Hyperplastic tissue, tumor tissue, or cancerous lesions may thus be treated by administering a therapeutically effective solution derived from a nanocrystalline antimicrobial or noble metal to the affected area; for example, as an infusion or instillation into a body cavity, e.g., the bladder to put the solution directly in contact with the bladder wall. Dressings or transdermal patches coated with the nanocrystalline antimicrobial metals may be applied internally in direct contact with hyperplastic tissue, tumor tissue, or cancerous lesion, and externally upon cancerous lesions, e.g., skin cancers such as melanoma. [0173]
  • EXAMPLES Example 1 Preparation of Nanocrystalline Silver Coatings on Dressings
  • This example shows the preparation of a bilayer nanocrystalline silver coating on a dressing material. A high density polyethylene dressing, DELNET™ or CONFORMANT 2™ was coated with a silver base layer and a silver/oxide top layer to generate a coloured antimicrobial coating having indicator value. The coating layers were formed by magnetron sputtering under the conditions set out in Table 1. [0174]
    TABLE 1
    Sputtering conditions
    Sputtering Conditions Base Layer Top Layer
    Target 99.99% Ag 99.99% Ag
    Target Size 20.3 cm diameter 20.3 cm diameter
    Working Gas 96/4 wt % Ar/O2 96/4 wt % Ar/O2
    Working Gas Pressure 5.33 Pa (40 mT) 5.33 Pa (40 mT)
    Power 0.3 kW 0.15 kW
    Substrate Temperature 20° C. 20° C.
    Base Pressure 3.0 × 10−6 Torr (4 × 10−4 Pa) 3.0 × 10−6 Torr (4 × 10−4 Pa)
    Anode/Cathode 100 mm 100 mm
    Distance
    Sputtering Time 7.5-9 mm 1.5 min
    Voltage 369-373 V 346 V
  • The resulting coating was blue in appearance. A fingertip touch was sufficient to cause a colour change to yellow. The base layer was about 900 nm thick, while the top layer was 100 nm thick. [0175]
  • To establish that silver species were released from the coated dressings, a zone of inhibition test was conducted. Mueller Hinton agar was dispensed into Petri dishes. The agar plates were allowed to surface dry prior to being inoculated with a lawn of [0176] Staphylococcus aureus ATCC No. 25923. The inoculant was prepared from Bactrol Discs (Difco, M.), which were reconstituted as per the manufacturer's directions. Immediately after inoculation, the coated materials to be tested were placed on the surface of the agar. The dishes were incubated for 24 hr. at 37° C. After this incubation period, the zone of inhibition was calculated (corrected zone of inhibition =zone of inhibition—diameter of the test material in contact with the agar). The results showed a corrected ZOI of about 10 mm, demonstrating good release of silver species.
  • The coating was analyzed by nitric acid digestion and atomic absorption analysis to contain 0.24+/−0.04 mg silver per mg high density polyethylene. The coating was a binary alloy of silver (>97%) and oxygen with negligible contaminants, based on secondary ion mass spectroscopy. The coating, as viewed by SEM, was highly porous and consisted of equiaxed nanocrystals organized into coarse columnar structures with an average grain size of 10 nm. Silver release studies in water demonstrated that silver was released continuously from the coating until an equilibrium concentration of about 66 mg/L was reached (determined by atomic absorption), a level that is 50 to 100 times higher than is expected from bulk silver metal (solubility ≦1 mg/L). [0177]
  • By varying the coating conditions for the top layer to lengthen the sputtering time to 2 min, 15 sec., a yellow coating was produced. The top layer had a thickness of about 140 nm and went through a colour change to purple with a fingertip touch. Similarly, a purple coating was produced by shortening the sputtering time to 1 min, to achieve a top layer thickness of about 65 nm. A fingertip touch caused a colour change to yellow. [0178]
  • To form a three layer dressing, two layers of this coated dressing material were placed above and below an absorbent core material formed from needle punched rayon/polyester (SONTARA™ 8411). With the silver coating on both the first and third layers, the dressing may be used with either the blue coating side or the silver side in the skin facing position. For indicator value, it might be preferable to have the blue coating visible. The three layers were laminated together by ultasonic welding to produce welds between all three layers spaced at about 2.5 cm intervals across the dressing. This allowed the dressing to be cut down to about 2.5 cm size portions for smaller dressing needs while still providing at least one weld in the dressing portion. [0179]
  • The coated dressings were sterilized using gamma radiation and a sterilization dose of 25 kGy. The finished dressing was packaged individually in sealed polyester peelable pouches, and has shown a shelf life greater than 1 year in this form. The coated dressings can be cut in ready to use sizes, such as 5.1×10.2 cm strips, before packaging. Alternatively, the dressings may be packaged with instructions for the patient or clinician to cut the dressing to size. [0180]
  • Additional silver coated dressings were prepared in a full scale roll coater under conditions to provide coatings having the same properties set out above, as follows: [0181]
  • i the dressing material included a first layer of silver coated DELNET, as set out above, laminated to STRATEX, AET, 8.0NP[0182] 2-A/QW, which is a layer of 100% rayon on a polyurethane film.
  • ii Silver Foam Dressing—three layers of silver coated high density polyethylene prepared as above, alternating with two layers of polyurethane foam, L-00562-6 Medical Foam, available from Rynel Ltd., Bootbay, Me., USA. [0183]
  • Example 2 Preparation of Atomic Disordered Nanocrystalline Silver Powders
  • Nanocrystalline silver coatings were prepared by sputtering silver in an oxygen-containing atmosphere directly onto an endless stainless steel belt of a magnetron sputtering roll coater, or onto silicon wafers on the belt. The belt did not need to be cooled. The coatings were scraped off with the belt with suspended metal scrapers as the belt rounded the end rollers. For the coated silicon wafers, the coatings were scraped off with a knife edge. The sputtering conditions were as follows: [0184]
    TABLE 2
    Sputtering Conditions
    Target 99.99% Ag
    Target Size 15.24 cm × 1216.125 cm
    (individual, 23
    targets)
    Working Gas 75:25 wt % Ar/O2
    Working Gas  5.33 Pa (40 mT)
    Pressure
    Total Current   40 A
    Base Pressure 5.0 × 10−5 Torr (range: 1 × 10−4 − 9 × 10−7 Torr or
    1 × 10−2 − 1.2 × 10−4 Pa)
    Sandvik Belt Speed  340 mm/mm
    Voltage  370 V
  • The powder had a particle size ranging from 2 μm to 100 μm, with grain or crystallite size of 8 to 10 nm (i.e., nanocrystalline), and demonstrated a positive rest potential. [0185]
  • Similar atomic disordered nanocrystalline silver powders were formed as set forth hereinabove by magnetron sputtering onto cooled steel collectors, under conditions taught in the prior Burrell et al. patents to produce atomic disorder. [0186]
  • Example 3 Preparation of Gels
  • No. 1 [0187]
  • A commercial carboxymethyl cellulose/pectin gel (DuoDERM™, ConvaTec Canada, 555, Dr. Frederik Philips, Suite 110, St-Laurent, Quebec, H4M 2×4) was combined with nanocrystalline silver powder prepared as set forth in Example 3 to produce a gel with 0.1% silver. A logarithmic reduction test was performed as follows in the gel using [0188] Pseudomonas aeruginosa. The inoculum was prepared by placing 1 bacteriologic loopful of the organism in 5 mL of trypticase soy broth and incubating it for 3-4 h. The inoculum (0.1 mL) was then added to 0.1 mL of gel and vortexed (triplicate samples). The mixture was incubated for one-half hour. Then 1.8 mL of sodium thioglycollate-saline (STS) solution was added to the test tube and vortexed. Serial dilutions were prepared on 10-1 to 10-7. A 011 mL aliquot of each dilution was plated in duplicate into Petri plates containing Mueller-Hinton agar. The plates were incubated for 48 h and then colonies were counted. Surviving members of organisms were determined and the logarithmic reduction compared to the initial inoculum was calculated. The logarithmic reduction for this mixture was 6.2, indicating a significant bactericidal effect.
  • No. 2 [0189]
  • Carboxymethyl cellulose (CMC) fibers were coated directly to produce an atomic disordered nanocrystalline silver coating, using magnetron sputtering conditions similar to those set forth in Example 1. The CMC was then gelled in water by adding 2.9 g to 100 mL volume. This material was tested using the method of No. 1. The material generated a 5.2 logarithmic reduction of [0190] Pseudomonas aeruginosa, demonstrating that the gel had a significant bactericidal effect.
  • No. 3 [0191]
  • An alginate fibrous substrate was directly coated with an atomic disordered nanocrystalline silver coating using magnetron sputtering conditions similar to those set forth in Example 1. The alginate (5.7 g) was added to 100 mL volume of water to create a gel. This material was tested using the method of No. 1. The material generated a 5.2 logarithmic reduction of [0192] Pseudomonas aeruginosa, demonstrating that the gel had a significant bactericidal effect.
  • No. 4 [0193]
  • A commercial gel containing CMC and alginate (Purilin gel, Coloplast) was mixed with a atomic disordered nanocrystalline silver powder to give a product with 0.1% silver. This was tested as above with both [0194] Pseudomonas aeruginosa and Staphylococcus aureus. Zone of inhibition data was also generated for this gel as follows. An inoculum (Pseudomonas aeruginosa and Staphylococcus aureus) was prepared as in No. 1 and 0.1 mL of this was spread onto the surface of Mueller-Hinton agar in a Petri dish. A six mm hole was then cut into the agar at the center of the Petri dish and removed. The well was filled with either 0.1 mL of the silver containing gel, a mupirocin containing cream or a mupirocin containing ointment. The Petri plates were then incubated for 24 h and the diameter of the zone of inhibition was measured and recorded.
  • The silver containing gel produced 9 mm zone of inhibition against both [0195] Pseudomonas aeruginosa and Staphylococcus aureus, while the mupirocin cream and ointment produced 42 and 48 mm zones against Staphylococcus aureus and 0 mm zones against Pseudomonas aeruginosa.
  • The silver containing gel reduced the [0196] Pseudomonas aeruginosa and Staphylococcus aureus properties by 4.4 and 0.6 log reductions, respectively, showing good bactericidal activity. The mupirocin cream and ointment generated 0.4 and 0.8, and 0.8 and 1.6, log reductions against Staphylococcus aureus and Pseudomonas aeruginosa, respectively. The silver gel had both a greater bactericidal effect and spectrum of activity than the mupirocin containing products.
  • Nos. 5-10 [0197]
  • The formula for Nos. 5-10 are summarized in Table 7. Zones of inhibitions were determined as in No. 4 and log reductions were determined as in No. 1. [0198]
  • All formulae provided a broader spectrum of activity and a greater bactericidal effect than did mupirocin in a cream or ointment form. The mupirocin cream produced zones of inhibition of 42 and 0, and log reduction of 0.4 and 0.8, against [0199] Staphylococcus aureus and Pseudomonas aeruginosa, respectively.
    TABLE 3
    Formulae for Gel Nos. 5-10 and Efficacy Results
    Silver Log Log
    CMC PVA Powder β- Methyl Propyl CZOI CZOI Red'n Red'n
    # (%) (%) (%) glucan paraben paraben S. aureus P. aeruginosa S. aureus P. aeruginosa
    5 2 0.1 11 13 1.4 >6
    6 2 0.5 0.1 0.1 0.02 14 15 3.3 >6
    7 2 0.5 0.1 13 14 2 N/A
    8 2 0.5 0.1 0.1 14 14 2 N/A
    9 2 0.5 0.1 0.20 14 14 2 N/A
    10  2 0.5 0.1 0.5 0.1 0.20 14 14 2 >6
  • No. 11 [0200]
  • A commercially available gel (glyceryl polymethacrylate) was blended with nanocrystalline silver powder of Example 3 to produce a gel with a silver content of 0.1%. This gel was tested as in Nos. 5-10 and was found to produce zones of 15 mm against both [0201] Staphylococcus aureus and Pseudomonas aeruginosa. Log reductions of 1.7 and >5 were produced against Staphylococcus aureus and Pseudomonas aeruginosa. This gel product had a greater spectrum of activity than did mupirocin cream or ointment.
  • Testing of the above preparations for antimicrobial effect was conducted to ensure that the antimicrobial metals, such as the nanocrystalline silver in these gels, are effectively released. [0202]
  • Example 4 Effects of Antimicrobial Silver on Apoptosis and Matrix Metalloproteinases in a Porcine Model
  • A porcine model was used to examine the effects of an antimicrobial metal formed with atomic disorder, preferably silver, on apoptosis and matrix metalloproteinases. Young, commercially produced, specific pathogen free domestic swine (20-25 kg) were used in these studies. The animals were conditioned in an animal facility for one week prior to any experimental manipulation. Typically, three animals were used in each experiment. The animals received water and hog ration (Unifeed™, Calgary, Alberta) without antibiotics ad libitum, were housed individually in suspended stainless steel cages (5′×6′), and maintained is a controlled environment with 12 hours of light per day. The study was approved by the University of Calgary Animal Care Committee and was conducted in accordance with guidelines established by the Canadian Council on Animal Care. [0203]
  • Antimicrobial silver metal was administered in the form of a dressing. The dressings included: [0204]
  • i) AB—nanocrystalline silver-coated dressing (the non-foam, three-layer dressing as set out in Example 1), comprising two layers of silver-coated high density polyethylene (HDPE) bonded on either side of an absorbent rayon/polyester core; [0205]
  • ii) AgHDPE—nanocrystalline silver coated HDPE layers aseptically separated from the absorbent core of the AB dressings; [0206]
  • iii) Control—identical in construction to the AB dressing except that the HDPE was not coated with nanocrystalline silver; [0207]
  • iv) Gauze—the absorbent rayon/polyester core of the AB dressings; [0208]
  • v) cHDPE—the uncoated HDPE aseptically removed from the absorbent core of the control dressings; and [0209]
  • vi) SN—sterile piece of the gauze dressing to which 24 μg silver /square inch (from silver nitrate) was added. This amount of silver is equivalent to the amount of silver released from a square inch of the AB dressing immersed in serum over a 24 hour period, as determined by atomic absorption analysis. [0210]
  • Dressings (i)-(iii) were gamma sterilized (25 kGy) prior to use. All dressings were moistened with sterile water prior to application to the incision. In some cases, the incisions were covered with a layer of occlusive polyurethane (Tegaderm™, 3M Corp., Minneapolis, Minn.). [0211]
  • Three isolates of bacteria were used in the inoculum, including [0212] Pseudomonas aeruginosa, Fusobacterium sp., and coagulase-negative staphylococci (CNS) (Culture Collection, University of Calgary, Calgary, Alberta). The bacterial strains were grown under appropriate conditions overnight prior to the day of surgery. On the morning of surgery, the organisms were washed with sterile water and resuspended to a final density of approximately 107 CFU/mL. The bacteria were mixed together in a ratio of 1:0.5:1 (Pseudomonas:CNS:Fusobacterium) in water. Sufficient inoculum was prepared to wet the incision created in each experiment. This procedure resulted in the incisions initially being evenly contaminated with approximately 8×104 CFU/cm2.
  • Prior to treatment, animals were sedated by an intramuscular injection of a mixture of 10 mg/kg ketamine (Ketalean™, MTC Pharmaceuticals, Cambridge, ON) and 0.2 mg/kg acepromazine (Atravet™, Ayerst Laboratories), followed by complete anesthesia induced by mask inhalation of 1-2% halothane (MTC Pharmaceuticals). Following induction of anesthesia, the dorsal and lateral thorax and abdomen of each animal was clipped using a #40 Osler blade and the skin subsequently scrubbed with a non-antibiotic soap, and allowed to dry prior to incision. [0213]
  • Animals typically received 20 full-thickness incisions, 10 on each side of the dorsal thorax. The incisions were created using a 2 cm diameter trephine. An epinephrine solution was then applied to the incisions to provide for complete hemostasis prior to inoculation. The incisions were contaminated by covering them with gauze sponges soaked with the bacterial inoculum. The wet sponges were covered with an occlusive barrier and allowed to stand for 15 minutes. In some instances, an incision was then sampled to determine the initial inoculum. Following any requisite sampling, the incisions were dressed with the appropriate dressings and covered with an occlusive layer that was secured with Elastoplast™ tape (Smith & Nephew, Lachine, QC). All animals received narcotic pain medication (Torbugesic™, Ayerst Laboratories, Montreal, QC, 0.2 mg/kg), as required. [0214]
  • The experimental and control groups are summarized in Table 4: [0215]
    TABLE 4
    Experimental and Control Groups
    Animal # Left Side (Silver Treatment) Right Side (Controls)
    Pig 1 Silver nitrate (SN) on gauze gauze moistened with water
    Pig 2 AgHDPE dHDPE
    Pig 3 AB control
  • A 2 cm diameter circle of the appropriate dressing was applied to each incision. For Pig 1, incisions on the left side were dressed with silver nitrate-moistened (SN) gauze, while control incisions on the right side received water-moistened gauze dressing. For Pig 2, the incisions on the left side were dressed with silver-coated HDPE (AgHDPE), while the control incisions on the right side received non-coated HDPE (cHDPE). For Pig 3, the incisions on the left side were dressed with AB dressing, while incisions on the right side received the vehicle control. For these experiments, each incision was individually covered with an occlusive film dressing (Tegaderm™, 3M Corp., Minneapolis, Minn.). [0216]
  • Each day following incision (up to 5 days), the dressing materials from each of the experimental and control groups were collected and pooled within each group. These dressing materials were then placed in conical centrifuge tube containing glass wool. The tubes and contents were centrifuged to remove all liquid from the dressings. The glass wool was then placed into a 5-mL syringe and pressed to recover the incision fluid from each of the six sample sets. The incisions were rebandaged in an identical manner to the original dressing format each time. Incision fluid which collected under the occlusive dressing was also aspirated and reserved for analysis. Due to the small volumes collected from each incision, it was necessary to pool the collected fluid from each of 10 incisions dressed with the same type of dressing. All incision fluids were stored at −80° C. until analysis. [0217]
  • Prior to enzyme zymography or activity assays, the protein concentrations of the incision fluid samples were compared to ensure that the protein levels in each sample were 10, similar. The samples were diluted 1:100 in water and assayed using the BCA Protein Assay System™ (Pierce Chemical, Rockford, Ill.). A standard curve was concurrently constructed using dilutions of bovine serum albumin. Incision fluid was diluted in water and then mixed with an equal volume of sample buffer (0.06 M Tris-HCl, pH 6.8; 12% SDS; 10% glycerol; 0.005% bromophenol blue). The samples were then electrophoresed on 10% polyacrylamide (BioRad, Mississauga, ON) gels containing 0. 1% gelatin. The proteins were then incubated in renaturing buffer (2.5% Triton™ X-100) for 90 minutes at 37° C. Following enzyme renaturation, the gels were incubated overnight in substrate buffer (50 mM Tri-HCl, pH 7.8; 5 mM CaCl[0218] 2; 200 mM NaCl; 0.02% Brij-35) with or without 10 mM 1,10 phenanthroline. The gels were subsequently stained with a standard Coomassie Blue stain and destained in methanol/acetic acid. Unless otherwise indicated, all chemicals were obtained from Sigma-Aldrich (Oakville, ON).
  • The incision fluid samples were assayed for the total amount of protein present. These values were between 30-80 mg/mL. The samples from individual animals were even more similar, varying by only 10-20 mg/mL in the pooled incision fluid. [0219]
  • i) Assay for Activity of Total MMPs [0220]
  • The total MMP activity of the incision fluid samples was determined by incubating diluted incision fluid with a quenched fluorescein-conjugated substrate (EnzChek DQ gelatin™, Molecular Probes, Eugene, Oreg.) for approximately 20 hours. Following incubation, the samples were read in a fluorometer (excitation 1=480 nm; emission 1=520 nm). Activity was compared to a collagenase standard as well as experimental versus control incision fluids. [0221]
  • FIG. 1 shows the change in total MMP activity from differently treated incision sites over a five-day period. The silver-coated HDPE (AgHDPE) results were essentially identical to those obtained using the silver-coated dressing (AB). Similarly, the gauze, non-coated HDPE (cHDPE), and control dressings yielded results essentially identical to each other and to untreated incisions under occlusion from which incision fluid was collected. Only the results from the control, silver-coated dressing (AB), silver-coated HDPE (AgHDPE), and silver nitrate moistened gauze (SN) are thus shown. The total MMP activity of the incision fluid sample from the control dressing was low for the first few days, then rose dramatically and remained high for the duration of the experiment. Similarly, the silver-nitrate moistened gauze (SN) demonstrated an almost identical pattern of total MMP activity. Results from the silver-coated dressing (AB) yielded dramatically different results. The level of MMP activity remained steady for the duration of the experiment and did not spike to high levels. Instead, it remained at a level roughly 60% lower than the highest level of activity reached in control or silver-nitrate moistened gauze (SN). [0222]
  • ii) Assay for Activity of Gelatinases [0223]
  • Gelatinases include MMP-2 (secreted by fibroblasts and a wide variety of other cell types) and MMP-9 (released by mononuclear phagocytes, neutrophils, corneal epithelial cells, tumor cells, cytotrophoblasts and keratinocytes). The gelatinases degrade gelatins (denatured collagens) and collagen type IV (basement membrane). Zymograms were run to examine changes in the levels and activity of MMP-9 and MMP-2 over the duration of the experiment. [0224]
  • Results of the zymograms for the control and silver nitrate moistened gauze (SN) appeared to be identical. The levels of MMP-9 declined over the period examined, particularly levels of the active form of MMP-9. The silver-coated dressing (AB) demonstrated higher levels of active MMP-9 than for the control. On Day 2, the silver-coated dressing (AB) showed lower levels of active MMP-9 than in the control. On Day 4, the silver-coated dressing (AB) showed little active MMP-9. In the control, the amount of the latent enzyme appeared to decrease while the active form of MMP-9 increased, particularly up to Day 4. [0225]
  • There was not much difference in the levels of MMP-2 activity for the silver-coated dressing (AB) over the duration of the experiment. However, there was an increase in the level of active MMP-2 in the control dressing by Day 5. It was also observed that the levels of some other, unidentified, gelatinolytic enzymes also decreased in the silver-coated dressing (AB) compared to the control. [0226]
  • iii) Assay of Total Protease Activity [0227]
  • Since MMPs have proteolytic activity, the total protease activity in incision fluid samples was assessed by incubating the samples with 3 mg/mL azocasein in 0.05 M Tris-HCl, pH 7.5 for 24 hours at 37° C. The undigested substrate was then precipitated by the addition of 20% trichloroacetic acid. The absorbance of the supernatant was then assessed using a spectrophotometer, 1=400 nm. The absorbance was compared to a standard curve prepared with bovine pancreatic trypsin. [0228]
  • Results paralleled those obtained in the total MMP assay above. The incision fluid samples for the control and silver nitrate moistened gauze (SN) demonstrated a pronounced increase in activity after Day 2 (FIG. 2). Incision fluid from the silver nitrate moistened gauze (SN) also demonstrated a marked increase in the total protease activity compared to control dressing incision fluid (FIG. 1). However, the total protease activity in the incision fluids of the silver coated dressings (AB) remained constant over the duration of the experiment. [0229]
  • Antimicrobial silver was thus demonstrated to be effective in modulating overall MMP activity. However, silver nitrate was not effective in modulating MMP activity in spite of the Ag[0230] + concentration being approximately the same levels as were expected to be released from the silver-coated dressing (AB) over the same period of time (24 h) between applications. The reason for the difference in effects may be related to the inherent nature of the two silver formulations. In the case of silver nitrate, although the silver was added to provide a similar final concentration of Ag+ as was anticipated to be released from the silver-coated dressing (AB), the Ag+ ions were added at once. It would thus be expected that the serum proteins and chlorides within the incision fluid would quickly inactivate a large portion of the Ag+. In the case of the silver-coated dressing (AB), the silver is continuously released to maintain a steady-state equilibrium, maintaining an effective level of silver in the incision for a prolonged period.
  • iv) Apoptosis [0231]
  • Histological assessment of cell apoptosis was carried out in order to determine whether the silver-coated dressing (AB) affected apoptosis within the incision. [0232]
  • Histological Observations of Porcine Tissue [0233]
  • Samples of tissue from the incisions were collected daily for the duration of the experiment, except for Day 1, and examined for evidence of apoptosis. The samples were fixed in 3.7% formaldehyde in PBS for 24 hours, then embedded in paraffin, and cut into 5 mm thick sections. The samples were then de-waxed with Clearing Solvent™ (Stephan's Scientific, Riverdale, N.J.) and rehydrated through an ethanol:water dilution series. The sections were treated with 20 mg/mL proteinase K (Qiagen, Germantown, MD) in 10 mM Tris-HCl (pH 7.4) for 30 minutes at room temperature. [0234]
  • Terminal deoxynucleotidyl transferase nick end labeling (TUNEL staining) was performed using an In Situ Cell Death Detection POD Kit™ (Boehringer Mannheim, Indianapolis, Ind.). Using this technique, cells which stain brown are those being eliminated by apoptosis. Endogenous peroxidase was blocked with 3% hydrogen peroxide in methanol for 10 minutes at room temperature then cells were permeabilized with 0.1% Triton™ X-1 00 (in 0. 1% sodium citrate) for 2 minutes on ice. After permeabilization, the samples were treated with the terminal transferase enzyme solution incubated in a humidified chamber at 37° C. for 60 minutes. Following labelling, the samples were washed once with 1.0% Triton™ X-100 and twice with PBS. The sections were incubated with Converter-POD™ (Boehringer Mannheim, Indianapolis, Ind.) in a humidified chamber at 37° C. for 30 minutes, and repeated washing with 1.0% Triton™ X-100 and PBS. Subsequently, the samples were incubated with DAB substrate (Vector Laboratory Inc., Burlingame, Calif.) for 10 minutes at room temperature and washed with 1.0% Triton™ X-100 and PBS. It was also necessary to counterstain the sections with hematoxylin nuclear counterstain (Vector Laboratory Inc., Burlingame, Calif.) for 10 seconds. [0235]
  • The prepared samples were then ready to be observed by light microscopy for evidence of apoptosis. For a positive control, the permeabilized sections were treated with 100 mg /mL DNase I in PBS for 10 minutes at room temperature to induce DNA strand breaks. For negative controls, the terminal transferase enzyme, POD or DAB were omitted between each labelling step. [0236]
  • In all samples examined, there was little difference between the control and silver nitrate moistened gauze (SN). However, significant apoptosis of the cell population was observed in incisions of the silver-coated dressing (AB). In the control incision, there were significant numbers of polymorphonuclear leukocytes (PMNs) and few fibroblasts, while in incisions of the silver-coated dressing (AB), there were significantly more fibroblasts and few PMNs. [0237]
  • Histopathological Scoring of Porcine Tissue [0238]
  • Animals were anesthetized as described above of Days 1, 4, and 7. A mid-incision biopsy was collected with a sterile 4 mm biopsy punch. The tissue was fixed in 10% neutral buffered formalin, embedded in methacrylate and sectioned (2-5 mm thick). The sections were stained with Lee's methylene blue and basic fuschin to demonstrate the cellular organization and bacteria. A pathologist blinded to the treatments scored the sections based on the presence of fibroblasts, PMNs and bacteria as follows: 0=absent; +=occasional with 1-5 per high power field of view; ++=moderate with 6-20 per high power field of view; +++=-abundant with 21-50per high power field of view; ++++=very abundant with more than 50 per high power field of view (Table 5). [0239]
    TABLE 5
    Histopathological Scoring of Porcine Tissue Collected on Days 1, 4 and 7
    Day
    Post-
    incision Dressing Fibroblasts PMNs Bacteria
    1 Silver-coated (AB) ++ ++ +
    1 Control 0 +++ ++++
    4 Silver-coated (AB) ++++ ++ 0
    4 Control + ++++ ++++
    7 Silver-coated (AB) ++++ + 0
    7 Control +++ +++ +++
  • The microscopic observation of the biopsy samples revealed that the infiltrating cell types were significantly different between the control and silver-coated dressings (AB). The control incisions were characterized by a large numbers of PMNs, while the silver-coated dressings (AB) demonstrated a larger proportion of fibroblasts and monocytes. The relative abundance of the fibroblasts in incisions of the silver-coated dressings (AB) became increasingly pronounced through to Day 7, as compared to the control incisions that remained populated largely by PMNs and monocytes. The staining method enabled staining also of bacteria, which was abundant in the control incision but generally absent in the incisions of the silver-coated dressings (AB). [0240]
  • Incisions treated with the nanocrystalline antimicrobial silver thus demonstrated more extensive apoptosis than did cells from incisions treated with either control or silver nitrate dressings. During the first two days following incision, the cell type which demonstrated the most pronounced increase in apoptosis were neutrophils. This suggests that part of the reason for the moderated neutrophil presence and the resultant modulation of MMP levels was due to neutrophil apoptosis. It has been shown that the number of apoptotic cells increases as the incision closes and that this is part of the mechanism involved in the decrease in cellularity of the maturing scar tissue (Desmouliere, A., Badid, C., Bochaton-Piallat, M. and Gabbiani, G. (1997) Apoptosis during wound healing, fibrocontractive diseases and vascular wall injury. [0241] Int. J. Biochem. Cell Biol. 29: 19-30.). The results suggest that the maturing of the nascent dermal and epidermal tissues may also be accelerated in the presence of the nanocrystalline antimicrobial metals. The findings indicated that acceleration in healing induced by the nanocrystalline antimicrobial metals is associated with a reduction of local MMP activity, as well as with an increased incidence of cell apoptosis within the incision.
  • All publications mentioned in this specification are indicative of the level of skill of those skilled in the art to which this invention pertains. All publications are herein incorporated by reference to the same extent as if each individual publication was specifically and individually indicated to be incorporated by reference. [0242]
  • The terms and expressions in this specification are, unless otherwise specifically defined herein, used as terms of description and not of limitation. There is no intention, in using such terms and expressions, of excluding equivalents of the features illustrated and described, it being recognized that the scope of the invention is defined and limited only by the claims which follow. [0243]

Claims (34)

    We claim:
  1. 1. A method of inducing apoptosis in a disease condition in a human or an animal, which comprises:
    contacting a hyperplastic tissue, a tumor tissue, or a cancerous lesion with a therapeutically effective amount of one or more antimicrobial metals in a crystalline form to provide a localized pro-apoptotic effect, wherein the one or more antimicrobial metals are characterized by sufficient atomic disorder, such that the metal, in contact with an alcohol or water-based electrolyte, releases atoms, ions, molecules, or clusters of at least one antimicrobial metal at a concentration sufficient to provide a localized pro-apoptotic effect.
  2. 2. The method as set forth in claim 1, wherein the one or more antimicrobial metals further inhibit one or more matrix metalloproteinases or modulate the production of the one or more matrix metalloproteinases.
  3. 3. The method as set forth in claim 2, wherein the antimicrobial metal is selected from the group consisting of silver, gold, platinum and palladium.
  4. 4. The method as set forth in claim 3, wherein the antimicrobial metal is nanocrystalline and is formed with sufficient atomic disorder such that, in contact with an alcohol or water based electrolyte, the antimicrobial metal releases ions, atoms, molecules or clusters of the antimicrobial metal on a sustainable basis.
  5. 5. The method as set forth in claim 4, wherein the tumor tissue is malignant.
  6. 6. The method as set forth in claim 4, wherein the tumor tissue or the cancerous lesion is skin cancer.
  7. 7. The method as set forth in claim 6, wherein the skin cancer is melanoma.
  8. 8. The method as set forth in claim 4, wherein the hyperplastic tissue, the tumor tissue, or the cancerous lesion is in the lung.
  9. 9. The method as set forth in claim 4, wherein the hyperplastic tissue, the tumor tissue, or the cancerous lesion is in the liver.
  10. 10. The method as set forth in claim 4, wherein the one or more matrix metalloproteinases are selected from the group consisting of collagenases, gelatinases, stromelysins, and stromelysin-like matrix metalloproteinases.
  11. 11. The method as set forth in claim 4, wherein the antimicrobial metal is nanocrystalline silver.
  12. 12. The method as set forth in claim 4, wherein the antimicrobial metal is silver, formed as a composite with oxygen.
  13. 13. The method as set forth in claim 4, wherein the antimicrobial metal is nanocrystalline gold.
  14. 14. The method as set forth in claim 4, wherein the antimicrobial metal is gold, formed as a composite with oxygen.
  15. 15. The method as set forth in claim 4, wherein the antimicrobial metal is nanocrystalline platinum.
  16. 16. The method as set forth in claim 4, wherein the antimicrobial metal is platinum, formed as a composite with oxygen.
  17. 17. The method as set forth in claim 4, wherein the one or more antimicrobial metals are provided as a coating on, or filler in, a dressing or a hydrated dressing, or in a pharmaceutical composition with one or more pharmaceutically and dermatogically acceptable carriers, diluents, or excipients suitable for topical application.
  18. 18. The method as set forth in claim 17, wherein the pharmaceutical composition includes a nanocrystalline powder of one or more antimicrobial metals, or a solution containing dissolved species from a nanocrystalline powder or coating of one or more antimicrobial metals.
  19. 19. The method as set forth in claim 18, wherein the pharmaceutical composition is a gel, cream, lotion, paste, or ointment containing the antimicrobial metal powder in an amount of 0.01-10% by weight, or a liquid formulated as a topical solution, spray, mist, drops, infusion or instillation containing 0.001-10% by weight of the antimicrobial metal.
  20. 20. The method as set forth in claim 19, wherein the antimicrobial metal is nanocrystalline silver.
  21. 21. The method as set forth in claim 19, wherein the antimicrobial metal is silver, formed as a composite with oxygen.
  22. 22. The method as set forth in claim 19, wherein the antimicrobial metal is nanocrystalline gold.
  23. 23. The method as set forth in claim 19, wherein the antimicrobial metal is gold, formed as a composite with oxygen.
  24. 24. The method as set forth in claim 19, wherein the antimicrobial metal is nanocrystalline platinum.
  25. 25. The method as set forth in claim 19, wherein the antimicrobial metal is platinum, formed as a composite with oxygen.
  26. 26. The method of claim 18, wherein the antimicrobial metal is in a powder form and is delivered directly to a locus of the hyperplastic tissue, the tumor tissue, or the cancerous lesion.
  27. 27. The method of claim 26, wherein the powder is sized with particulates no larger than 2 μm.
  28. 28. The method of claim 27, wherein the powder is sized with particulates no larger than 1 μm.
  29. 29. The method of claim 28, wherein the antimicrobial metal is nanocrystalline silver.
  30. 30. The method of claim 28, wherein the antimicrobial metal is nanocrystalline silver, formed as a composite with oxygen.
  31. 31. The method as set forth in claim 28, wherein the antimicrobial metal is nanocrystalline gold.
  32. 32. The method as set forth in claim 28, wherein the antimicrobial metal is gold, formed as a composite with oxygen.
  33. 33. The method as set forth in claim 28, wherein the antimicrobial metal is nanocrystalline platinum.
  34. 34. The method as set forth in claim 28, wherein the antimicrobial metal is platinum, formed as a composite with oxygen.
US10131568 2001-04-23 2002-04-23 Method of induction of apoptosis and inhibition of matrix metalloproteinases using antimicrobial metals Abandoned US20030021854A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US28588401 true 2001-04-23 2001-04-23
US09840637 US7008647B2 (en) 2001-04-23 2001-04-23 Treatment of acne
US10131568 US20030021854A1 (en) 2001-04-23 2002-04-23 Method of induction of apoptosis and inhibition of matrix metalloproteinases using antimicrobial metals

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US10131568 US20030021854A1 (en) 2001-04-23 2002-04-23 Method of induction of apoptosis and inhibition of matrix metalloproteinases using antimicrobial metals
US10159587 US7001617B2 (en) 2001-04-23 2002-05-30 Method of induction of apoptosis and inhibition of matrix metalloproteinases using antimicrobial metals
US10277298 US6989157B2 (en) 2000-07-27 2002-10-22 Dry powders of metal-containing compounds
US10277320 US20030206966A1 (en) 2000-07-27 2002-10-22 Methods of inducing apoptosis and modulating metalloproteinases
US10277362 US20030194444A1 (en) 2000-07-27 2002-10-22 Methods of treating skin and integument conditions
US10277358 US20030185901A1 (en) 2000-07-27 2002-10-22 Methods of treating conditions with a metal-containing material
US10364983 US7078060B2 (en) 2000-07-27 2003-02-12 Solutions and aerosols of metal-containing compounds
US10690715 US20040191329A1 (en) 2000-07-27 2003-10-22 Compositions and methods of metal-containing materials
US10690724 US7427416B2 (en) 2000-07-27 2003-10-22 Methods of treating conditions using metal-containing materials
US10690774 US7255881B2 (en) 2000-07-27 2003-10-22 Metal-containing materials
US10770132 US7201925B2 (en) 2002-04-23 2004-02-02 Treatment of ungual and subungual diseases
US10985204 US7470437B2 (en) 2000-07-27 2004-11-10 Methods of treating conditions with a metal-containing material
US10998499 US20050136128A1 (en) 2000-07-27 2004-11-29 Dry powders of metal-containing compounds
US11250516 US20060115541A1 (en) 2000-07-27 2005-10-14 Treatment of bladder conditions
US11893134 US20080014286A1 (en) 2000-07-27 2007-08-14 Metal-containing materials

Related Parent Applications (3)

Application Number Title Priority Date Filing Date
US09840637 Continuation-In-Part US7008647B2 (en) 2001-04-23 2001-04-23 Treatment of acne
US10131511 Continuation-In-Part US6939568B2 (en) 2001-04-23 2002-04-23 Treatment of inflammatory skin conditions
US10690774 Continuation-In-Part US7255881B2 (en) 2000-07-27 2003-10-22 Metal-containing materials

Related Child Applications (11)

Application Number Title Priority Date Filing Date
US10128208 Continuation-In-Part US6989156B2 (en) 2001-04-23 2002-04-23 Therapeutic treatments using the direct application of antimicrobial metal compositions
US10159587 Continuation-In-Part US7001617B2 (en) 2001-04-23 2002-05-30 Method of induction of apoptosis and inhibition of matrix metalloproteinases using antimicrobial metals
US10277358 Continuation-In-Part US20030185901A1 (en) 2000-07-27 2002-10-22 Methods of treating conditions with a metal-containing material
US10277356 Continuation-In-Part US20030170314A1 (en) 2000-07-27 2002-10-22 Compositions of metal-containing compounds
US10277362 Continuation-In-Part US20030194444A1 (en) 2000-07-27 2002-10-22 Methods of treating skin and integument conditions
US10277320 Continuation-In-Part US20030206966A1 (en) 2000-07-27 2002-10-22 Methods of inducing apoptosis and modulating metalloproteinases
US10277298 Continuation-In-Part US6989157B2 (en) 2000-07-27 2002-10-22 Dry powders of metal-containing compounds
US10690774 Continuation-In-Part US7255881B2 (en) 2000-07-27 2003-10-22 Metal-containing materials
US10690724 Continuation-In-Part US7427416B2 (en) 2000-07-27 2003-10-22 Methods of treating conditions using metal-containing materials
US10690715 Continuation-In-Part US20040191329A1 (en) 2000-07-27 2003-10-22 Compositions and methods of metal-containing materials
US10770132 Continuation-In-Part US7201925B2 (en) 2000-07-27 2004-02-02 Treatment of ungual and subungual diseases

Publications (1)

Publication Number Publication Date
US20030021854A1 true true US20030021854A1 (en) 2003-01-30

Family

ID=26963436

Family Applications (9)

Application Number Title Priority Date Filing Date
US10131513 Active 2021-09-22 US6723350B2 (en) 2001-04-23 2002-04-23 Lubricious coatings for substrates
US10131509 Active US7087249B2 (en) 2001-04-23 2002-04-23 Treatment of mucosal membranes
US10128208 Expired - Fee Related US6989156B2 (en) 2001-04-23 2002-04-23 Therapeutic treatments using the direct application of antimicrobial metal compositions
US10131568 Abandoned US20030021854A1 (en) 2001-04-23 2002-04-23 Method of induction of apoptosis and inhibition of matrix metalloproteinases using antimicrobial metals
US10131511 Active 2021-08-07 US6939568B2 (en) 2001-04-23 2002-04-23 Treatment of inflammatory skin conditions
US10772672 Abandoned US20040157073A1 (en) 2001-04-23 2004-02-05 Lubricious coatings for substrates
US11174104 Abandoned US20050271743A1 (en) 2001-04-23 2005-07-01 Treatment of inflammatory skin conditions
US11284507 Abandoned US20060083792A1 (en) 2001-04-23 2005-11-22 Therapeutic treatments using the direct application of antimicrobial metal compositions
US11434958 Abandoned US20060204591A1 (en) 2001-04-23 2006-05-16 Treatment of mucosal membranes

Family Applications Before (3)

Application Number Title Priority Date Filing Date
US10131513 Active 2021-09-22 US6723350B2 (en) 2001-04-23 2002-04-23 Lubricious coatings for substrates
US10131509 Active US7087249B2 (en) 2001-04-23 2002-04-23 Treatment of mucosal membranes
US10128208 Expired - Fee Related US6989156B2 (en) 2001-04-23 2002-04-23 Therapeutic treatments using the direct application of antimicrobial metal compositions

Family Applications After (5)

Application Number Title Priority Date Filing Date
US10131511 Active 2021-08-07 US6939568B2 (en) 2001-04-23 2002-04-23 Treatment of inflammatory skin conditions
US10772672 Abandoned US20040157073A1 (en) 2001-04-23 2004-02-05 Lubricious coatings for substrates
US11174104 Abandoned US20050271743A1 (en) 2001-04-23 2005-07-01 Treatment of inflammatory skin conditions
US11284507 Abandoned US20060083792A1 (en) 2001-04-23 2005-11-22 Therapeutic treatments using the direct application of antimicrobial metal compositions
US11434958 Abandoned US20060204591A1 (en) 2001-04-23 2006-05-16 Treatment of mucosal membranes

Country Status (7)

Country Link
US (9) US6723350B2 (en)
EP (4) EP1390013A4 (en)
JP (4) JP2004525980A (en)
CA (4) CA2445729C (en)
DE (2) DE60210441T2 (en)
ES (1) ES2261659T3 (en)
WO (5) WO2002085299A3 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040259445A1 (en) * 2003-06-23 2004-12-23 Beiersdorf Ag Antimicrobial composite
US20050196463A1 (en) * 2004-03-03 2005-09-08 Stiles James Alexander R. NO-containing complexes
US20060057369A1 (en) * 2003-06-23 2006-03-16 Beiersdorf Ag Antimicrobial composite
US20080014247A1 (en) * 2006-06-30 2008-01-17 Nucryst Pharmaceuticals Metal-containing formulations and methods of use
US20090162448A1 (en) * 2007-12-20 2009-06-25 Nucryst Pharmaceuticals Corp. Metal Carbonate Particles and Methods of Making Thereof
US20120237584A1 (en) * 2006-01-13 2012-09-20 3M Innovative Properties Company Silver-containing antimicrobial articles and methods of manufacture
US9440001B2 (en) 2013-03-06 2016-09-13 Specialty Fibres and Materials Limited Absorbent materials

Families Citing this family (242)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7135195B2 (en) * 1999-06-01 2006-11-14 American Silver, Llc Treatment of humans with colloidal silver composition
US8535728B2 (en) 1999-06-01 2013-09-17 American Silver, Llc Colloidal silver composition having antimicrobial properties
US9549842B2 (en) 2011-02-04 2017-01-24 Joseph E. Kovarik Buccal bioadhesive strip and method of treating snoring and sleep apnea
US7179849B2 (en) 1999-12-15 2007-02-20 C. R. Bard, Inc. Antimicrobial compositions containing colloids of oligodynamic metals
US8088060B2 (en) 2000-03-15 2012-01-03 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
US9522217B2 (en) 2000-03-15 2016-12-20 Orbusneich Medical, Inc. Medical device with coating for capturing genetically-altered cells and methods for using same
US20040092890A1 (en) * 2001-05-10 2004-05-13 Ash Stephen R. Catheter lock solution including a photo-oxidant
US20030185901A1 (en) * 2000-07-27 2003-10-02 Burrell Robert E. Methods of treating conditions with a metal-containing material
US7427416B2 (en) * 2000-07-27 2008-09-23 Nucryst Pharmaceuticals Corp. Methods of treating conditions using metal-containing materials
US7201925B2 (en) * 2002-04-23 2007-04-10 Nueryst Pharmaceuticals Corp. Treatment of ungual and subungual diseases
WO2004037187A3 (en) * 2002-10-22 2004-09-02 Robert E Burrell Metal-containing materials, compositions and methods
US20060115541A1 (en) * 2000-07-27 2006-06-01 Gillis Scott H Treatment of bladder conditions
DE10043151A1 (en) * 2000-08-31 2002-03-28 Peter Steinruecke Bone cement with antimicrobial activity
US7700819B2 (en) 2001-02-16 2010-04-20 Kci Licensing, Inc. Biocompatible wound dressing
US7763769B2 (en) 2001-02-16 2010-07-27 Kci Licensing, Inc. Biocompatible wound dressing
CA2445729C (en) * 2001-04-23 2013-07-02 Nucryst Pharmaceuticals Corp. Use of metals to treat mucosal membranes
US7008647B2 (en) * 2001-04-23 2006-03-07 Nucryst Pharmaceuticals Corp. Treatment of acne
US20030059375A1 (en) * 2001-08-20 2003-03-27 Transave, Inc. Method for treating lung cancers
DE10146050B4 (en) * 2001-09-18 2007-11-29 Bio-Gate Ag A process for producing an antimicrobial adhesive and coating material
JP3795364B2 (en) * 2001-09-27 2006-07-12 シャープ株式会社 Integrated circuit and a receiving device
WO2003047636A3 (en) 2001-12-03 2003-10-02 Bard Inc C R Microbe-resistant medical device, microbe-resistant polymeric coating and methods for producing same
US8118789B2 (en) * 2002-02-20 2012-02-21 Abbott Research Group, Inc. Deodorizer devices and systems for controlling perspiration-related body odor
US7270653B2 (en) * 2002-02-20 2007-09-18 Abbott Research Group Methods of treating abnormal biological conditions using metal oxides
US6589216B1 (en) 2002-02-20 2003-07-08 Abbott Research Group, Inc. Vaginal douches, vaginal douche applicators and methods of vaginal douching
JP2006511930A (en) * 2002-06-21 2006-04-06 コンティ テミック ミクロエレクトロニック ゲーエムベーハー Printed circuit board for an electronic vehicle control system
US6865810B2 (en) * 2002-06-27 2005-03-15 Scimed Life Systems, Inc. Methods of making medical devices
US20040101553A1 (en) * 2002-08-02 2004-05-27 Transave, Inc. Platinum aggregates and process for producing the same
US9186322B2 (en) * 2002-08-02 2015-11-17 Insmed Incorporated Platinum aggregates and process for producing the same
US8404751B2 (en) * 2002-09-27 2013-03-26 Hallux, Inc. Subunguicide, and method for treating onychomycosis
US7485259B2 (en) * 2002-10-08 2009-02-03 Eldred Bradley J Organic compound and metal ion synergistic disinfection and purification system and method of manufacture
US8066854B2 (en) * 2002-12-18 2011-11-29 Metascape Llc Antimicrobial coating methods
US20050008676A1 (en) 2002-12-19 2005-01-13 Yongxing Qiu Medical devices having antimicrobial coatings thereon
US7666410B2 (en) 2002-12-20 2010-02-23 Kimberly-Clark Worldwide, Inc. Delivery system for functional compounds
US8409618B2 (en) * 2002-12-20 2013-04-02 Kimberly-Clark Worldwide, Inc. Odor-reducing quinone compounds
EP1442753B1 (en) * 2003-02-03 2007-02-21 Polaschegg, Hans-Dietrich, Dr.techn. Composition for the prevention of indwelling device related infection
US20040151716A1 (en) * 2003-02-03 2004-08-05 Hamer Richard A. Material and method for treating microbial mediated dermatological conditions
US20040156874A1 (en) * 2003-02-11 2004-08-12 Bradley Pharmaceuticals, Inc. Urea- a topical anti-inflammatory
CA2512434C (en) * 2003-02-26 2012-01-03 Otsuka Pharmaceutical Co., Ltd. Sustained-release pharmaceutical composition comprising carrageenan for lung administration
US20040180093A1 (en) * 2003-03-12 2004-09-16 3M Innovative Properties Company Polymer compositions with bioactive agent, medical articles, and methods
US7488757B2 (en) * 2003-03-24 2009-02-10 Becton, Dickinson And Company Invisible antimicrobial glove and hand antiseptic
US20040236290A1 (en) * 2003-04-23 2004-11-25 Zimmermann Stephan A. Minimally invasive vascular apparatus modified to minimize scarring at introduction site
US6874165B2 (en) * 2003-05-19 2005-04-05 Mao-Sheng Lee Modified NBR gloves
WO2004108091A3 (en) 2003-06-06 2005-05-12 Univ Texas Antimicrobial flush solutions
US7480530B2 (en) * 2003-06-30 2009-01-20 Johnson & Johnson Consumer Companies, Inc. Device for treatment of barrier membranes
US8734421B2 (en) * 2003-06-30 2014-05-27 Johnson & Johnson Consumer Companies, Inc. Methods of treating pores on the skin with electricity
US20050025817A1 (en) * 2003-07-03 2005-02-03 Bhatia Kuljit S. Delivery system for topical medications
DK200301128A (en) * 2003-08-05 2005-02-06 Thomsen Joern Oddershede Grant Preparation
US20050028563A1 (en) * 2003-08-08 2005-02-10 Milliken & Company Garment for use with sensitive skin, and method and fabric for us in making same
DE10340277B4 (en) * 2003-08-29 2006-11-23 Bio-Gate Bioinnovative Materials Gmbh Personal care products with silver agglomerates
US8519146B2 (en) * 2004-09-07 2013-08-27 The University Of Akron Metal complexes of N-heterocyclic carbenes as antibiotics
US20050054774A1 (en) * 2003-09-09 2005-03-10 Scimed Life Systems, Inc. Lubricious coating
US7879350B2 (en) 2003-10-16 2011-02-01 Kimberly-Clark Worldwide, Inc. Method for reducing odor using colloidal nanoparticles
US7794737B2 (en) 2003-10-16 2010-09-14 Kimberly-Clark Worldwide, Inc. Odor absorbing extrudates
US7678367B2 (en) 2003-10-16 2010-03-16 Kimberly-Clark Worldwide, Inc. Method for reducing odor using metal-modified particles
US20050123590A1 (en) * 2003-12-05 2005-06-09 3M Innovative Properties Company Wound dressings and methods
US7745509B2 (en) * 2003-12-05 2010-06-29 3M Innovative Properties Company Polymer compositions with bioactive agent, medical articles, and methods
US20050123621A1 (en) * 2003-12-05 2005-06-09 3M Innovative Properties Company Silver coatings and methods of manufacture
WO2005058199A1 (en) * 2003-12-16 2005-06-30 Avery Dennison Corporation Electrostatically self-assembled antimicrobial coating for medical applications
DE10359338B4 (en) * 2003-12-17 2007-07-19 Heraeus Kulzer Gmbh Antimicrobial nanosilver additive for polymerisable dental materials
GB0401821D0 (en) * 2004-01-28 2004-03-03 Qinetiq Nanomaterials Ltd Method of manufacture of polymer composites
US20050256553A1 (en) * 2004-02-09 2005-11-17 John Strisower Method and apparatus for the treatment of respiratory and other infections using ultraviolet germicidal irradiation
US7457667B2 (en) * 2004-02-19 2008-11-25 Silverleaf Medical Products, Inc. Current producing surface for a wound dressing
US7662176B2 (en) * 2004-02-19 2010-02-16 Vomaris Innovations, Inc. Footwear apparatus and methods of manufacture and use
US20070065522A1 (en) * 2004-03-18 2007-03-22 Transave, Inc. Administration of high potency platinum compound formulations by inhalation
JP2007529546A (en) * 2004-03-18 2007-10-25 トランセイブ, インク.Transave, Inc. Administration of cisplatin by inhalation
US20050271746A1 (en) * 2004-05-18 2005-12-08 Abbott Chun L Topical treatments for abnormal biological conditions and method of topically treating such conditions
US7758892B1 (en) * 2004-05-20 2010-07-20 Boston Scientific Scimed, Inc. Medical devices having multiple layers
WO2005112957A1 (en) * 2004-05-21 2005-12-01 Transave, Inc. Treatment of lung diseases and pre-lung disease conditions
US20060275223A1 (en) * 2005-06-02 2006-12-07 Burr James B Erythritol compositions for teeth and gums
DE102004031955A1 (en) * 2004-06-24 2006-01-12 Paul Hartmann Ag wound dressing
US20060002967A1 (en) * 2004-07-01 2006-01-05 Smestad Thomas L Resorbable implant with lubricious coating
US20060035039A1 (en) * 2004-08-12 2006-02-16 3M Innovative Properties Company Silver-releasing articles and methods of manufacture
US20060034899A1 (en) * 2004-08-12 2006-02-16 Ylitalo Caroline M Biologically-active adhesive articles and methods of manufacture
CN2734238Y (en) * 2004-08-25 2005-10-19 任晓艳 Nano silver coated suture line
US20060068024A1 (en) * 2004-09-27 2006-03-30 Schroeder Kurt M Antimicrobial silver halide composition
JP5735724B2 (en) * 2004-11-08 2015-06-17 インスメッド, インコーポレイテッド The lipid-based platinum compound formulations administered intraperitoneally using, for cancer treatment methods
CN101107039A (en) * 2004-11-23 2008-01-16 国际生物治疗研究公司 Method of delivery of therapeutic metal ions, alloys and salts
US20090191247A1 (en) * 2004-12-06 2009-07-30 Nanotechnologies, Inc Anti-Viral Uses Of Carbon And Metal Nanomaterial Compositions
EP1842524B1 (en) * 2004-12-13 2013-01-23 APT Co., Ltd. Cleaning liquid for oral cavity
US7749529B2 (en) * 2005-02-08 2010-07-06 Ash Access Technology, Inc. Catheter lock solution comprising citrate and a paraben
WO2006090239A1 (en) * 2005-02-23 2006-08-31 Kerryne Krause-Neufeldt Cosmetic product
DE102005008416B4 (en) * 2005-02-24 2011-09-29 Lohmann & Rauscher Gmbh & Co. Kg A method for purifying marine collagen
US8864730B2 (en) 2005-04-12 2014-10-21 Rochester Medical Corporation Silicone rubber male external catheter with absorbent and adhesive
US8399027B2 (en) * 2005-04-14 2013-03-19 3M Innovative Properties Company Silver coatings and methods of manufacture
CN101563116A (en) * 2005-07-21 2009-10-21 Fmc生物聚合物联合股份有限公司 Medical devices coated with a fast dissolving biocompatible coating
WO2007013100A1 (en) * 2005-07-26 2007-02-01 Virchow Biotech Private Limited Gel formulation comprising platelet derived growth factor
DE102005041005A1 (en) * 2005-08-29 2007-03-01 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Composition, useful to prepare e.g. biocides and anti-fouling compositions, comprises nano-particulate silver and further a component of silver salts, nano-particulate zinc oxide, chitosan and its derivative
US20070185432A1 (en) * 2005-09-19 2007-08-09 Transport Pharmaceuticals, Inc. Electrokinetic system and method for delivering methotrexate
WO2007056263A3 (en) * 2005-11-08 2007-11-08 Jin K Lee Methods of treating cancer with high potency lipid-based platinum compound formulations administered intravenously
WO2007056236A3 (en) * 2005-11-08 2007-09-20 Mary E Neville Methods of treating cancer with lipid-based platinum compound formulations administered intravenously
US9107824B2 (en) 2005-11-08 2015-08-18 Insmed Incorporated Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
US20070190182A1 (en) * 2005-11-08 2007-08-16 Pilkiewicz Frank G Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
US20070122350A1 (en) * 2005-11-30 2007-05-31 Transave, Inc. Safe and effective methods of administering therapeutic agents
EP1954327A4 (en) * 2005-12-01 2012-03-28 Innograft Llc Method for ionically cross-linking polysaccharide material for thin film applications and products produced therefrom
US8840660B2 (en) 2006-01-05 2014-09-23 Boston Scientific Scimed, Inc. Bioerodible endoprostheses and methods of making the same
US20070166344A1 (en) * 2006-01-18 2007-07-19 Xin Qu Non-leaching surface-active film compositions for microbial adhesion prevention
US8089029B2 (en) 2006-02-01 2012-01-03 Boston Scientific Scimed, Inc. Bioabsorbable metal medical device and method of manufacture
CA2641021C (en) * 2006-02-01 2015-07-07 Hollister Incorporated Methods of applying a hydrophilic coating to a substrate, and substrates having a hydrophilic coating
US7687650B2 (en) 2006-02-03 2010-03-30 Jr Chem, Llc Chemical compositions and methods of making them
US7897800B2 (en) * 2006-02-03 2011-03-01 Jr Chem, Llc Chemical compositions and methods of making them
GB0603487D0 (en) * 2006-02-22 2006-04-05 Agt Sciences Ltd Delivery means
US20070212425A1 (en) * 2006-03-09 2007-09-13 Barna Ivan J Cidal formulations and methods of use
US20070224244A1 (en) * 2006-03-22 2007-09-27 Jan Weber Corrosion resistant coatings for biodegradable metallic implants
US20070224288A1 (en) * 2006-03-22 2007-09-27 Kiss Nail Products, Inc. Antibacterial gel coating and pedicure spa with antibacterial function
JP5226661B2 (en) * 2006-04-06 2013-07-03 ターロ ファーマシューティカルズ ノース アメリカ インコーポレイテッド Novel spill resistant formulation comprising a hydrocolloid polymer
EP2005990B1 (en) * 2006-04-07 2013-08-28 Hisamitsu Pharmaceutical Co., Inc. Microneedle device and transdermal administration device provided with microneedles
US8048150B2 (en) * 2006-04-12 2011-11-01 Boston Scientific Scimed, Inc. Endoprosthesis having a fiber meshwork disposed thereon
US8273381B1 (en) 2006-04-14 2012-09-25 Auburn University Compositions for and methods of controlling olfactory responses to odorants
ES2349262T3 (en) 2006-06-14 2010-12-29 Nm Tech Ltd. Nanomaterials And Microdevices Technology Nanomaterials for biomedical coatings bone anchored.
US20070292397A1 (en) * 2006-06-19 2007-12-20 Mcnulty Amy K Method for the detection and neutralization of bacteria
WO2007149868A3 (en) * 2006-06-20 2008-07-03 Univ California Controlled release encapsulated anti-bacterial and anti-inflammatory nanoparticles
US8197452B2 (en) * 2006-07-28 2012-06-12 Becton, Dickinson And Company Vascular access device non-adhering surfaces
US8512294B2 (en) * 2006-07-28 2013-08-20 Becton, Dickinson And Company Vascular access device antimicrobial materials and solutions
US20080027410A1 (en) * 2006-07-28 2008-01-31 Becton, Dickinson And Company Vascular access device non-adhering membranes
CA2659761A1 (en) 2006-08-02 2008-02-07 Boston Scientific Scimed, Inc. Endoprosthesis with three-dimensional disintegration control
EP2068780A2 (en) * 2006-09-15 2009-06-17 Boston Scientific Limited Medical devices
EP2959925B1 (en) 2006-09-15 2018-08-29 Boston Scientific Limited Medical devices and methods of making the same
US7955382B2 (en) * 2006-09-15 2011-06-07 Boston Scientific Scimed, Inc. Endoprosthesis with adjustable surface features
ES2368125T3 (en) * 2006-09-15 2011-11-14 Boston Scientific Scimed, Inc. bioerodible endoprostheses biostable inorganic layers.
US20080071353A1 (en) * 2006-09-15 2008-03-20 Boston Scientific Scimed, Inc. Endoprosthesis containing magnetic induction particles
US8808726B2 (en) * 2006-09-15 2014-08-19 Boston Scientific Scimed. Inc. Bioerodible endoprostheses and methods of making the same
WO2008036457A3 (en) * 2006-09-18 2008-05-29 Boston Scient Scimed Inc Controlling biodegradation of a medical instrument
CA2663762A1 (en) * 2006-09-18 2008-03-27 Boston Scientific Limited Endoprostheses
JP2010503486A (en) * 2006-09-18 2010-02-04 ボストン サイエンティフィック リミテッド Endoprosthesis
US7867522B2 (en) 2006-09-28 2011-01-11 Jr Chem, Llc Method of wound/burn healing using copper-zinc compositions
WO2008043396A1 (en) * 2006-10-12 2008-04-17 Nm Tech Nanomaterials Microdevice Technology Ltd. Material, item and products comprising a composition having anti-microbial properties
US20100098949A1 (en) * 2006-10-18 2010-04-22 Burton Scott A Antimicrobial articles and method of manufacture
US20080097577A1 (en) * 2006-10-20 2008-04-24 Boston Scientific Scimed, Inc. Medical device hydrogen surface treatment by electrochemical reduction
US20080103459A1 (en) * 2006-10-30 2008-05-01 Anthony Di Salvo Enzyme inhibition using nanoparticles
US20080122582A1 (en) * 2006-11-29 2008-05-29 Texas Instruments Incorporated Location Based Portable Device Feature Disabler
US20080132991A1 (en) * 2006-11-30 2008-06-05 Leonard Pinchuk Method for Ionically Cross-Linking Gellan Gum for Thin Film Applications and Medical Devices Produced Therefrom
US20080147734A1 (en) * 2006-12-18 2008-06-19 Cuticeuticals, Inc Method of topical steroidal organization
DE602007010669D1 (en) 2006-12-28 2010-12-30 Boston Scient Ltd hear it
WO2008097661A1 (en) * 2007-02-09 2008-08-14 Poniard Pharmaceuticals, Inc. Stabilized picoplatin oral dosage form
WO2008112596A3 (en) * 2007-03-09 2008-10-30 Anthem Orthopaedics Llc Implantable device with bioabsorbable layer, kit and method for use therewith, and apparatus for preparing same
US20080226701A1 (en) * 2007-03-15 2008-09-18 John Deignan Medicated patches
EP2155324A1 (en) * 2007-04-20 2010-02-24 Nitric Biotherapeutics, Inc. A single use applicator cartridge for an electrokinetic delivery system and method for self administration of medicaments
US20100069957A1 (en) * 2007-04-25 2010-03-18 Ferass Abuzaina Coated Filaments
US8309222B2 (en) * 2007-04-25 2012-11-13 Covidien Lp Coated filaments
KR20080070482A (en) * 2007-05-31 2008-07-30 (주)디딤바이오텍 A lubricating composition comprising agents which induce the mucosal immunity and a preparation method thereof
US20080312580A1 (en) * 2007-06-15 2008-12-18 Transport Pharmaceuticals, Inc. Current concentration system and method for electrokinetic delivery of medicaments
US8133553B2 (en) 2007-06-18 2012-03-13 Zimmer, Inc. Process for forming a ceramic layer
US20080319371A1 (en) * 2007-06-19 2008-12-25 Transport Pharmaceuticals, Inc. Method and system for treating of onychomycosis with an applicator having a gel medicament layer
US8309521B2 (en) 2007-06-19 2012-11-13 Zimmer, Inc. Spacer with a coating thereon for use with an implant device
JP5159183B2 (en) * 2007-06-22 2013-03-06 アイノベックス株式会社 Composition for the improvement or treatment of infertility
DE102007031650A1 (en) 2007-07-06 2009-01-08 Stada Arzneimittel Ag Dermatological agent for the treatment and / or care of the skin in atopic dermatitis
US8052745B2 (en) 2007-09-13 2011-11-08 Boston Scientific Scimed, Inc. Endoprosthesis
EP2200619B1 (en) * 2007-09-28 2015-08-12 Johnson & Johnson Consumer Companies, Inc. Electricity-generating particulates and the use thereof
ES2319064B1 (en) * 2007-10-05 2010-02-15 Universidad De Santiago De Compostela Using atomic quantum clusters (AQC) as antimicrobials and biocides.
US20110230973A1 (en) * 2007-10-10 2011-09-22 Zimmer, Inc. Method for bonding a tantalum structure to a cobalt-alloy substrate
US8608049B2 (en) * 2007-10-10 2013-12-17 Zimmer, Inc. Method for bonding a tantalum structure to a cobalt-alloy substrate
US20090143855A1 (en) * 2007-11-29 2009-06-04 Boston Scientific Scimed, Inc. Medical Device Including Drug-Loaded Fibers
EP2231216B1 (en) * 2007-12-14 2012-08-08 Boston Scientific Scimed, Inc. Drug-eluting endoprosthesis
US20090163887A1 (en) * 2007-12-20 2009-06-25 Arehart Kelly D Odor control cellulose granules with quinone compounds
US8273791B2 (en) 2008-01-04 2012-09-25 Jr Chem, Llc Compositions, kits and regimens for the treatment of skin, especially décolletage
US20090187256A1 (en) * 2008-01-21 2009-07-23 Zimmer, Inc. Method for forming an integral porous region in a cast implant
US20090198286A1 (en) * 2008-02-05 2009-08-06 Zimmer, Inc. Bone fracture fixation system
US20090255843A1 (en) * 2008-04-11 2009-10-15 Andrew Charles Krakowski Systems and kits for treatment methods
EP3144346A1 (en) * 2008-04-24 2017-03-22 Medtronic Inc. Rehydratable polysaccharide particles
CN102883715B (en) 2008-04-24 2014-11-12 麦德托尼克公司 Chitosan-containing protective composition
US9198997B2 (en) 2008-04-24 2015-12-01 Medtronic, Inc. Rehydratable thiolated polysaccharide particles and sponge
WO2009132227A1 (en) 2008-04-24 2009-10-29 Medtronic, Inc. Protective gel based on chitosan and oxidized polysaccharide
US8506944B2 (en) * 2008-05-07 2013-08-13 The Regents Of The University Of California Replenishment and enrichment of ocular surface lubrication
DK2915529T3 (en) * 2008-05-07 2017-08-07 Univ California Therapeutic regeneration and enrichment of the ocular surface lubrication
US7998192B2 (en) * 2008-05-09 2011-08-16 Boston Scientific Scimed, Inc. Endoprostheses
US8389583B2 (en) 2008-05-23 2013-03-05 Zurex Pharma, Inc. Antimicrobial compositions and methods of use
US8236046B2 (en) * 2008-06-10 2012-08-07 Boston Scientific Scimed, Inc. Bioerodible endoprosthesis
US20100004733A1 (en) * 2008-07-02 2010-01-07 Boston Scientific Scimed, Inc. Implants Including Fractal Structures
US7985252B2 (en) 2008-07-30 2011-07-26 Boston Scientific Scimed, Inc. Bioerodible endoprosthesis
US20100030170A1 (en) * 2008-08-01 2010-02-04 Keith Alan Keller Absorptive Pad
US20100082088A1 (en) * 2008-08-27 2010-04-01 Ali Fassih Treatment of sweating and hyperhydrosis
US8150525B2 (en) * 2008-08-27 2012-04-03 Johnson & Johnson Consumer Companies, Inc. Treatment of hyperhydrosis
US20110207807A1 (en) * 2008-09-02 2011-08-25 Catholic University Industry Academy Cooperation Foundation New use for homoisoflavone or a salt thereof
US8382824B2 (en) * 2008-10-03 2013-02-26 Boston Scientific Scimed, Inc. Medical implant having NANO-crystal grains with barrier layers of metal nitrides or fluorides
EP2218447B1 (en) * 2008-11-04 2017-04-19 PharmaSol GmbH Compositions containing lipid micro- or nanoparticles for the enhancement of the dermal action of solid particles
US20100124568A1 (en) * 2008-11-20 2010-05-20 Med-Eez, Inc Pharmaceutical articles coated with lubricious coatings
US8551517B2 (en) * 2008-12-16 2013-10-08 Kimberly-Clark Worldwide, Inc. Substrates providing multiple releases of active agents
WO2010085753A1 (en) 2009-01-23 2010-07-29 Jr Chem, Llc Rosacea treatments and kits for performing them
US8267992B2 (en) 2009-03-02 2012-09-18 Boston Scientific Scimed, Inc. Self-buffering medical implants
US20100229282A1 (en) * 2009-03-11 2010-09-16 Ansell Limited Powder-Free Anti-Blocking Coated Glove
US9149567B2 (en) * 2009-03-11 2015-10-06 Ansell Limited Powder-free antimicrobial coated glove
US20100234925A1 (en) * 2009-03-16 2010-09-16 PinPoint U.S.A., Inc. Treatment of microbiological pathogens in a toe nail with antimicrobial light
US20120089232A1 (en) 2009-03-27 2012-04-12 Jennifer Hagyoung Kang Choi Medical devices with galvanic particulates
CA2763221A1 (en) * 2009-05-26 2010-12-16 The General Hospital Corporation Method and apparatus for dermal delivery of a substance
WO2010144044A1 (en) 2009-06-10 2010-12-16 Exthera Ab Use of a composition for the treatment of mucositis
US9192626B2 (en) 2009-06-10 2015-11-24 American Silver, Llc Dental uses of silver hydrosol
US8821455B2 (en) * 2009-07-09 2014-09-02 Becton, Dickinson And Company Antimicrobial coating for dermally invasive devices
US20110008271A1 (en) * 2009-07-13 2011-01-13 Jr Chem, Llc Rosacea treatments using polymetal complexes
US20110022158A1 (en) * 2009-07-22 2011-01-27 Boston Scientific Scimed, Inc. Bioerodible Medical Implants
US8814922B2 (en) * 2009-07-22 2014-08-26 New Star Lasers, Inc. Method for treatment of fingernail and toenail microbial infections using infrared laser heating and low pressure
US20110065798A1 (en) * 2009-09-17 2011-03-17 Becton, Dickinson And Company Anti-infective lubricant for medical devices and methods for preparing the same
US20110091571A1 (en) * 2009-10-16 2011-04-21 Moore Michael F Method of controlling the propagation of mrsa, staph and other infections that colonize in the nose
EP2498764B1 (en) 2009-11-09 2017-09-06 Spotlight Technology Partners LLC Fragmented hydrogels
WO2011057131A1 (en) 2009-11-09 2011-05-12 Spotlight Technology Partners Llc Polysaccharide based hydrogels
US8744567B2 (en) * 2009-11-13 2014-06-03 Johnson & Johnson Consumer Companies, Inc. Galvanic skin treatment device
US10086018B2 (en) 2011-02-04 2018-10-02 Joseph E. Kovarik Method and system for reducing the likelihood of colorectal cancer in a human being
US9987224B2 (en) 2011-02-04 2018-06-05 Joseph E. Kovarik Method and system for preventing migraine headaches, cluster headaches and dizziness
JP2011135009A (en) * 2009-12-25 2011-07-07 Tokyo Electron Ltd Method and apparatus for drying substrate
KR20110091461A (en) * 2010-02-05 2011-08-11 존슨 앤드 존슨 컨수머 캄파니즈, 인코포레이티드 Lip compositions comprising galvanic particulates
US20110212042A1 (en) * 2010-03-01 2011-09-01 Prithwiraj Maitra Skin care composition having desirable bulk color
US8668732B2 (en) * 2010-03-23 2014-03-11 Boston Scientific Scimed, Inc. Surface treated bioerodible metal endoprostheses
US20110236491A1 (en) * 2010-03-25 2011-09-29 Jeannette Chantalat Topical anti-inflammatory composition
US9999702B2 (en) 2010-04-09 2018-06-19 Kci Licensing Inc. Apparatuses, methods, and compositions for the treatment and prophylaxis of chronic wounds
US20110301553A1 (en) * 2010-06-04 2011-12-08 Smiths Medical Asd, Inc. Antimicrobial lubricant
RU2452498C2 (en) * 2010-07-20 2012-06-10 Общество с ограниченной ответственностью "Научно-производственное объединение "Ликом" Method for preparing anti-tuberculosis drug
US9572880B2 (en) 2010-08-27 2017-02-21 Sienna Biopharmaceuticals, Inc. Ultrasound delivery of nanoparticles
ES2637373T3 (en) 2010-08-27 2017-10-13 Sienna Biopharmaceuticals, Inc. Compositions and methods for directed thermomodulation
JP5646277B2 (en) * 2010-10-25 2014-12-24 クラシエホームプロダクツ株式会社 Fungicide and treatment and prevention agents of acne
US9572329B2 (en) * 2010-11-18 2017-02-21 Samuel P Hopkins Antimicrobial containing fish hook and method of using and manufacturing same
US8952057B2 (en) 2011-01-11 2015-02-10 Jr Chem, Llc Compositions for anorectal use and methods for treating anorectal disorders
US8701671B2 (en) 2011-02-04 2014-04-22 Joseph E. Kovarik Non-surgical method and system for reducing snoring
CA2863587A1 (en) 2011-02-16 2012-08-23 The General Hospital Corporation Optical coupler for an endoscope
US9707375B2 (en) 2011-03-14 2017-07-18 Rochester Medical Corporation, a subsidiary of C. R. Bard, Inc. Catheter grip and method
JPWO2012131931A1 (en) * 2011-03-30 2014-07-24 ダイワボウホールディングス株式会社 Wound dressing
GB2497115A (en) * 2011-12-01 2013-06-05 Lrc Products Coated condom
JP6017883B2 (en) * 2012-08-08 2016-11-02 バイオエポック株式会社 Method for producing a toothpaste
CN102872159A (en) * 2012-09-29 2013-01-16 广东同德药业有限公司 Nano-silver chitosan gel foam preparation for treating vaginal bacterial inflammation, and preparation method thereof
CA2887687A1 (en) 2012-10-11 2014-04-17 Nanocomposix, Inc. Silver nanoplate compositions and methods
CN102872160A (en) * 2012-10-26 2013-01-16 广东同德药业有限公司 Nano-silver foaming agent used for sterilizing wounds of scalds and burns and ulcer wounds
US20140120168A1 (en) * 2012-10-26 2014-05-01 Nanocomposix, Inc. Metastable silver nanoparticle composites
US9872969B2 (en) 2012-11-20 2018-01-23 Rochester Medical Corporation, a subsidiary of C.R. Bard, Inc. Catheter in bag without additional packaging
US10092728B2 (en) 2012-11-20 2018-10-09 Rochester Medical Corporation, a subsidiary of C.R. Bard, Inc. Sheath for securing urinary catheter
US20140377318A1 (en) * 2012-12-06 2014-12-25 S. Douglas Cornell Antimicrobial sanitizer systems and methods of killing or inhibiting pathogens
EP2764876A1 (en) * 2013-02-11 2014-08-13 Lacerta Technologies Inc. Bone substitute material with biologically active coating
US9750928B2 (en) 2013-02-13 2017-09-05 Becton, Dickinson And Company Blood control IV catheter with stationary septum activator
US9695323B2 (en) 2013-02-13 2017-07-04 Becton, Dickinson And Company UV curable solventless antimicrobial compositions
US9327095B2 (en) 2013-03-11 2016-05-03 Becton, Dickinson And Company Blood control catheter with antimicrobial needle lube
US9750927B2 (en) 2013-03-11 2017-09-05 Becton, Dickinson And Company Blood control catheter with antimicrobial needle lube
US20140276493A1 (en) * 2013-03-15 2014-09-18 Braden King-Fung Leung Wound healing compositions
US20140271919A1 (en) * 2013-03-15 2014-09-18 Chun Lim Abbott Topical Copper Ion Treatments and Methods of Treatment Using Topical Copper Ion Treatments in the Genital-Rectal Areas of the Body
US20140271495A1 (en) * 2013-03-15 2014-09-18 Chun Lim Abbott Topical Copper Ion Treatments and Methods of Treatment Using Topical Copper Ion Treatments in the Oral-Respiratory-Otic Areas of the Body
US9095566B1 (en) * 2013-06-28 2015-08-04 Edward Quicksilver Yavitz Eyelash and eyelid margin infections
JP2017500960A (en) 2013-12-30 2017-01-12 ボストン サイエンティフィック サイムド,インコーポレイテッドBoston Scientific Scimed,Inc. Function lubricating medical device coating
CN104814831A (en) * 2014-01-30 2015-08-05 柯惠有限合伙公司 Preparation of occlusive dressings
US9789279B2 (en) 2014-04-23 2017-10-17 Becton, Dickinson And Company Antimicrobial obturator for use with vascular access devices
US9675793B2 (en) 2014-04-23 2017-06-13 Becton, Dickinson And Company Catheter tubing with extraluminal antimicrobial coating
US9459442B2 (en) 2014-09-23 2016-10-04 Scott Miller Optical coupler for optical imaging visualization device
CN104577135B (en) * 2015-01-04 2017-01-18 哈尔滨工业大学 Method for preparing a three-dimensional network of silver
RU2611999C2 (en) * 2015-08-05 2017-03-01 Федеральное государственное бюджетное учреждение науки Иркутский институт химии им. А.Е. Фаворского Сибирского отделения Российской академии наук Silver nanocomposite based on arabinogalactan conjugate and flavonoids with antimicrobial and antitumor action and preparation method thereof
US10040957B2 (en) * 2015-09-17 2018-08-07 Eastman Kodak Company Ink jettable, UV-curable compositions
CN108601930A (en) * 2016-02-08 2018-09-28 奥巴斯尼茨医学公司 Drug-eluting balloon
RU2659580C1 (en) * 2017-10-16 2018-07-05 Федеральное государственное бюджетное образовательное учреждение высшего образования "Кировский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО Кировский ГМУ Минздрава России) Method for obtaining agent for topical treatment of skin lesions based on nanoscale silver particles, ointment base and solid additives

Citations (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3757786A (en) * 1970-11-06 1973-09-11 D Smith Synthetic surgical sutures
US3800792A (en) * 1972-04-17 1974-04-02 Johnson & Johnson Laminated collagen film dressing
US3918446A (en) * 1974-05-03 1975-11-11 E Med Corp Securement device for intravenous catheter and its tubing
US4059105A (en) * 1976-03-24 1977-11-22 Omnimed, Inc. Cannula securing device
US4324237A (en) * 1980-02-26 1982-04-13 E-Med Corporation Intravenous catheter and tubing securement and dressing device with a window over the puncture or wound site
US4355636A (en) * 1979-07-21 1982-10-26 Dragerwerk Ag Humdifier and heater for air to be inhaled for connection to an inhalation conduit of a respirator
US4476590A (en) * 1980-03-27 1984-10-16 National Research Development Corporation Antimicrobial surgical implants
US4581028A (en) * 1984-04-30 1986-04-08 The Trustees Of Columbia University In The City Of New York Infection-resistant materials and method of making same through use of sulfonamides
US4596556A (en) * 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4633863A (en) * 1985-09-27 1987-01-06 Filips Chester P Arterial anchor bandage
US4749572A (en) * 1984-08-28 1988-06-07 Pharmaceutical Holdings Limited Pharmaceutical preparations
US4790824A (en) * 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4803066A (en) * 1986-03-22 1989-02-07 Smith & Nephew Associated Companies P.L.C. Antibacterial and/or antifungal compositions for topical application
US4847049A (en) * 1985-12-18 1989-07-11 Vitaphore Corporation Method of forming chelated collagen having bactericidal properties
US4952411A (en) * 1987-02-25 1990-08-28 Trustees Of Columbia University In The City Of New York Method of inhibiting the transmission of AIDS virus
US4960413A (en) * 1985-11-09 1990-10-02 The Shirley Institute Wound dressing
US5019096A (en) * 1988-02-11 1991-05-28 Trustees Of Columbia University In The City Of New York Infection-resistant compositions, medical devices and surfaces and methods for preparing and using same
US5064413A (en) * 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5122418A (en) * 1985-12-09 1992-06-16 Shiseido Company Ltd. Composite powder and production process
US5143717A (en) * 1987-12-30 1992-09-01 Code Blue Medical Corporation Burn foam and delivery system
US5236421A (en) * 1986-05-28 1993-08-17 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Fixing system for fastening catheters, cannulas or the like to the skin surface and process for the sterile fastening thereof
US5270358A (en) * 1989-12-28 1993-12-14 Minnesota Mining And Manufacturing Company Composite of a disperesed gel in an adhesive matrix
US5312335A (en) * 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5372589A (en) * 1993-11-24 1994-12-13 Davis; W. Gordon Fenestrated transparent catheter securing device and method
US5383851A (en) * 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5454889A (en) * 1993-08-19 1995-10-03 Ici Canada Inc. Prill coating
US5457015A (en) * 1991-09-03 1995-10-10 Minnesota Mining And Manufacturing Company Silver halide coated organic polymeric films utilizing chitosan acid salt antistatic protection layers
US5534288A (en) * 1993-03-23 1996-07-09 United States Surgical Corporation Infection-resistant surgical devices and methods of making them
US5569207A (en) * 1994-10-13 1996-10-29 Quinton Instrument Company Hydrocolloid dressing
US5578073A (en) * 1994-09-16 1996-11-26 Ramot Of Tel Aviv University Thromboresistant surface treatment for biomaterials
US5631066A (en) * 1993-01-25 1997-05-20 Chronopol, Inc. Process for making metalized films and films produced therefrom
US5744151A (en) * 1995-06-30 1998-04-28 Capelli; Christopher C. Silver-based pharmaceutical compositions
US5770255A (en) * 1992-05-19 1998-06-23 Westaim Technologies, Inc. Anti-microbial coating for medical devices
US5792793A (en) * 1993-11-05 1998-08-11 Meiji Milk Products Co., Ltd. Antibacterial, antifungal and antiviral agent
US5895419A (en) * 1996-09-30 1999-04-20 St. Jude Medical, Inc. Coated prosthetic cardiac device
US5899880A (en) * 1994-04-08 1999-05-04 Powderject Research Limited Needleless syringe using supersonic gas flow for particle delivery
US5945032A (en) * 1996-09-30 1999-08-31 Basf Aktiengesellschaft Polymer/hydrogen peroxide complexes
US5981822A (en) * 1997-05-02 1999-11-09 Johnson & Johnson Medical, Inc. Absorbent wound dressings
US6010478A (en) * 1995-02-14 2000-01-04 Powderject Research Limited Trans-mucosal particle delivery
US6013050A (en) * 1995-10-20 2000-01-11 Powderject Research Limited Particle delivery
US6022547A (en) * 1994-12-06 2000-02-08 Helene Curtis, Inc. Rinse-off water-in-oil-in-water compositions
US6071543A (en) * 1997-06-02 2000-06-06 Cellegy Pharmaceuticals, Inc. Pyridine-thiols reverse mucocutaneous aging
US6071541A (en) * 1998-07-31 2000-06-06 Murad; Howard Pharmaceutical compositions and methods for managing skin conditions
US6096002A (en) * 1998-11-18 2000-08-01 Bioject, Inc. NGAS powered self-resetting needle-less hypodermic jet injection apparatus and method
US6123925A (en) * 1998-07-27 2000-09-26 Healthshield Technologies L.L.C. Antibiotic toothpaste
US6126931A (en) * 1993-12-20 2000-10-03 Surfacine Development Company, Llc Contact-killing antimicrobial devices
US6165440A (en) * 1997-07-09 2000-12-26 Board Of Regents, The University Of Texas System Radiation and nanoparticles for enhancement of drug delivery in solid tumors
US6187290B1 (en) * 1994-12-06 2001-02-13 Giltech Limited Physiologically acceptable foamable formulation and foam
US6197351B1 (en) * 1995-06-07 2001-03-06 Robert S. Neuwirth Intrauterine chemical necrosing method and composition
US6201164B1 (en) * 1996-07-11 2001-03-13 Coloplast A/S Hydrocolloid wound gel
US6258385B1 (en) * 1999-04-22 2001-07-10 Marantech Holding, Llc Tetrasilver tetroxide treatment for skin conditions
US20010010016A1 (en) * 1999-03-31 2001-07-26 Shanta Modak Triclosan and silver compound containing medical devices
US6277169B1 (en) * 1997-02-24 2001-08-21 Superior Micropowders Llc Method for making silver-containing particles
US20020001628A1 (en) * 1999-11-24 2002-01-03 Mikio Ito Pharmaceutical composition for preventing and/or curing digestive disorders
US20020016585A1 (en) * 2000-07-29 2002-02-07 Sachse Hans E. Catheter with a bio-resorbable coating for preventing ascending infections
US6365130B1 (en) * 1998-11-23 2002-04-02 Agion Technologies L.L.C. Antimicrobial chewing gum
US20020045049A1 (en) * 1997-06-20 2002-04-18 Madsen Niels Joergen Hydrophilic coating and a method for the preparation thereof
US6720006B2 (en) * 1999-06-17 2004-04-13 Bernhard Hanke Anti-microbial body care product

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB420052A (en) 1932-10-17 1934-11-23 Consortium Elektrochem Ind Manufacture of shaped articles from polyvinyl alcohols
FR732895A (en) 1932-10-18 1932-09-25 Consortium Elektrochem Ind Objects spun polyvinyl alcohol
FR882M (en) 1961-01-18 1961-10-06
GB1270410A (en) 1969-09-25 1972-04-12 Allor Corp Colloidal composition and method of preparing the same
US3988434A (en) * 1972-08-07 1976-10-26 Schole Murray L Dental preparation
DE2748882A1 (en) 1977-11-02 1979-05-03 Arnis Dr Med Rava Plaster protecting wound against infection - esp. during application of intravenous catheter, permitting continuous use for ten days
GB2073024B (en) 1980-03-27 1984-06-27 Nat Res Dev Antimicrobial surgical implants
JPH0255485B2 (en) 1982-01-21 1990-11-27 Nippon Steel Corp
GB2140684B (en) 1983-04-25 1986-07-30 Stavros Christodoulou Mineral oil composition for use in the treatment of eczema
JPS6021912A (en) 1983-07-14 1985-02-04 Mitsubishi Rayon Co Ltd Manufacture of metallized synthetic fiber staple
US4828832A (en) 1983-09-07 1989-05-09 Laboratorios Biochemie De Mexico Method of manufacturing a composition for treating skin lesions
EP0136768A3 (en) 1983-09-07 1986-07-30 Laboratorios Biochemie De Mexico S.A. DE C.V. Composition and method for treatingskin lesions
JPS62185807A (en) * 1986-02-08 1987-08-14 Mitsubishi Shindo Kk Production of metallic flat powder
GB8612598D0 (en) 1986-05-23 1986-07-02 Tarnpure Ltd Liquid/gas interface apparatus
EP0254413A3 (en) * 1986-06-13 1989-11-08 Ito, Jin-ichi Silver-ionic water and its uses
DE3807944A1 (en) 1988-03-10 1989-09-21 Braun Melsungen Ag Device for fastening a catheter or a cannula on the skin surface
US4956350A (en) 1988-08-18 1990-09-11 Minnesota Mining And Manufacturing Company Wound filling compositions
US4908355A (en) 1989-01-09 1990-03-13 Dow Corning Corporation Skin treatment method
JP3169621B2 (en) * 1991-01-29 2001-05-28 シナネン株式会社 Antibacterial external preparation
EP0570452A1 (en) 1991-02-06 1993-11-24 Minnesota Mining And Manufacturing Company Improved surgical hardware with bacteriostatic silver coating, and method of using same
US5484886A (en) * 1991-04-25 1996-01-16 Merck & Co., Inc. Human neurokinin-1 receptor
US5958440A (en) 1992-05-19 1999-09-28 Westaim Technologies, Inc. Anti-microbial materials
CA2136455C (en) * 1993-11-18 1999-06-29 Robert Edward Burrell Process for producing anti-microbial effect with complex silver ions
CN1034090C (en) 1992-08-06 1997-02-19 蒋建华 Producing method for long-acting broad spectrum antiseptic fabric
JP2981528B2 (en) 1992-12-25 1999-11-22 三菱電機株式会社 A cathode ray tube and a method of manufacturing the same
JP3513199B2 (en) * 1993-01-01 2004-03-31 キヤノン株式会社 A liquid ejecting head, a liquid jet head cartridge and recording apparatus using the same, and manufacturing method for a liquid jet head
US5848995A (en) 1993-04-09 1998-12-15 Walder; Anthony J. Anti-infective medical article and method for its preparation
US5454886A (en) 1993-11-18 1995-10-03 Westaim Technologies Inc. Process of activating anti-microbial materials
EP0681841A1 (en) * 1993-11-26 1995-11-15 Kimurakogyo Co., Ltd. $i(IN VIVO) FREE-RADICAL GENERATOR
JPH07220702A (en) * 1994-02-02 1995-08-18 Nec Corp Battery pack
US5563132A (en) 1994-06-21 1996-10-08 Bodaness; Richard S. Two-step cancer treatment method
US6544357B1 (en) * 1994-08-01 2003-04-08 Franz Hehmann Selected processing for non-equilibrium light alloys and products
DE19541735A1 (en) 1995-11-09 1997-05-15 Iris Roller Use of hydrothermal rock deposits e.g. calcite precursors
US5686096A (en) 1995-12-22 1997-11-11 Becton Dickinson And Company Medical device for the protection of a catheter penetration site
EP0834319A1 (en) * 1996-10-07 1998-04-08 Kartar Dr. Lalvani Mineral and vitamin combinations in arthritic pain
GB9623962D0 (en) * 1996-11-15 1997-01-08 Tillotts Pharma Ag Pharmaceutical composition
US6333093B1 (en) 1997-03-17 2001-12-25 Westaim Biomedical Corp. Anti-microbial coatings having indicator properties and wound dressings
KR20010012464A (en) 1997-05-12 2001-02-15 세이지 파마슈티칼스, 인크. Topical spray for burn treatment and anti-infection
KR20010013377A (en) * 1997-06-04 2001-02-26 데이비드 엠 모이어 Mild, leave-on antimicrobial compositions
DE19728489A1 (en) 1997-07-03 1999-01-07 Huels Chemische Werke Ag Medical safety device for improving the skin fixation of indwelling catheters and other transcutaneous implants with a reduced risk of infection
US6153210A (en) * 1997-08-14 2000-11-28 Periodontix, Inc. Use of locally delivered metal ions for treatment of periodontal disease
JP3411195B2 (en) * 1997-08-18 2003-05-26 栄一 築地 Active oxygen scavenger
JPH11116488A (en) * 1997-10-08 1999-04-27 Toagosei Co Ltd Carcinostatic agent
JP4039719B2 (en) * 1997-10-17 2008-01-30 富士フイルム株式会社 Anti-tumor agent
US6312643B1 (en) * 1997-10-24 2001-11-06 The United States Of America As Represented By The Secretary Of The Air Force Synthesis of nanoscale aluminum alloy powders and devices therefrom
FR2775696B1 (en) * 1998-03-05 2000-04-14 Saint Gobain Vitrage Substrate has photocatalytic coating
US20020014406A1 (en) * 1998-05-21 2002-02-07 Hiroshi Takashima Aluminum target material for sputtering and method for producing same
ES2212645T3 (en) * 1998-10-23 2004-07-16 Avery Dennison Corporation Process for the manufacture of metal flakes.
US6238986B1 (en) * 1998-11-06 2001-05-29 Advanced Micro Devices, Inc. Formation of junctions by diffusion from a doped film at silicidation
US6436422B1 (en) 1998-11-23 2002-08-20 Agion Technologies L.L.C. Antibiotic hydrophilic polymer coating
JP4454062B2 (en) * 1999-05-17 2010-04-21 三宅 實興子 Ultra-fine silver milk-like body, and a method of manufacturing the same
CN1161511C (en) 1999-07-27 2004-08-11 蒋建华 Long-acting wide-spectrum antiseptic nanometer silver fabirc and its making method
CN1108786C (en) 1999-12-28 2003-05-21 天津市化妆品科学技术研究所 Siver foil cosmetics
US7137968B1 (en) 2000-03-13 2006-11-21 Nucryst Pharmaceuticals Corp. Transcutaneous medical device dressings and method of use
US6224898B1 (en) 2000-03-23 2001-05-01 The United States Of America As Represented By The Secretary Of The Army Antimicrobial dendrimer nanocomposites and a method of treating wounds
US6719987B2 (en) * 2000-04-17 2004-04-13 Nucryst Pharmaceuticals Corp. Antimicrobial bioabsorbable materials
US6592888B1 (en) 2000-05-31 2003-07-15 Jentec, Inc. Composition for wound dressings safely using metallic compounds to produce anti-microbial properties
US20030170314A1 (en) * 2000-07-27 2003-09-11 Burrell Robert E. Compositions of metal-containing compounds
ES2231528T3 (en) * 2000-07-27 2005-05-16 Nucryst Pharmaceuticals Corp. Use of noble for the manufacture of a medicament for the tratamientyo disorders and hyperproliferative skin diseases metals.
CN1279222A (en) 2000-07-31 2001-01-10 金华尖峰陶瓷有限责任公司 Antibacterial inorganic ceramics and its production technology
CN1291667A (en) 2000-08-14 2001-04-18 骏安科技投资有限公司 Nanometer silver anti-bacteria cloth and its industrial production technology
CN1147640C (en) 2000-09-19 2004-04-28 南京希科集团有限公司 Method for making antibacterial fabric containing nm-class silver
CN1159488C (en) 2001-01-20 2004-07-28 南京希科集团有限公司 Antibacterial flexble material containing nano silver and its preparing process and application
CN1179646C (en) 2001-04-20 2004-12-15 朱红军 Aggregation-preventing nano broad spectrum antibacterial silver powder and its inductrial production process
CA2445729C (en) * 2001-04-23 2013-07-02 Nucryst Pharmaceuticals Corp. Use of metals to treat mucosal membranes
US7008647B2 (en) 2001-04-23 2006-03-07 Nucryst Pharmaceuticals Corp. Treatment of acne
CN1183285C (en) 2001-04-25 2005-01-05 朱红军 Industrial production process of aggregation-preventing wide-spectrum nanometer antibiotic silver yarn
CN102299308B (en) 2011-09-03 2014-05-07 深圳市贝特瑞新能源材料股份有限公司 Lithium ion battery cathode material, and preparation method and lithium ion battery thereof

Patent Citations (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3757786A (en) * 1970-11-06 1973-09-11 D Smith Synthetic surgical sutures
US3800792A (en) * 1972-04-17 1974-04-02 Johnson & Johnson Laminated collagen film dressing
US3918446A (en) * 1974-05-03 1975-11-11 E Med Corp Securement device for intravenous catheter and its tubing
US4059105A (en) * 1976-03-24 1977-11-22 Omnimed, Inc. Cannula securing device
US4355636A (en) * 1979-07-21 1982-10-26 Dragerwerk Ag Humdifier and heater for air to be inhaled for connection to an inhalation conduit of a respirator
US4324237A (en) * 1980-02-26 1982-04-13 E-Med Corporation Intravenous catheter and tubing securement and dressing device with a window over the puncture or wound site
US4476590A (en) * 1980-03-27 1984-10-16 National Research Development Corporation Antimicrobial surgical implants
US4581028A (en) * 1984-04-30 1986-04-08 The Trustees Of Columbia University In The City Of New York Infection-resistant materials and method of making same through use of sulfonamides
US4749572A (en) * 1984-08-28 1988-06-07 Pharmaceutical Holdings Limited Pharmaceutical preparations
US4596556A (en) * 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4633863A (en) * 1985-09-27 1987-01-06 Filips Chester P Arterial anchor bandage
US4960413A (en) * 1985-11-09 1990-10-02 The Shirley Institute Wound dressing
US5122418A (en) * 1985-12-09 1992-06-16 Shiseido Company Ltd. Composite powder and production process
US4847049A (en) * 1985-12-18 1989-07-11 Vitaphore Corporation Method of forming chelated collagen having bactericidal properties
US4803066A (en) * 1986-03-22 1989-02-07 Smith & Nephew Associated Companies P.L.C. Antibacterial and/or antifungal compositions for topical application
US5236421A (en) * 1986-05-28 1993-08-17 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Fixing system for fastening catheters, cannulas or the like to the skin surface and process for the sterile fastening thereof
US4952411A (en) * 1987-02-25 1990-08-28 Trustees Of Columbia University In The City Of New York Method of inhibiting the transmission of AIDS virus
US4790824A (en) * 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US5143717A (en) * 1987-12-30 1992-09-01 Code Blue Medical Corporation Burn foam and delivery system
US5019096A (en) * 1988-02-11 1991-05-28 Trustees Of Columbia University In The City Of New York Infection-resistant compositions, medical devices and surfaces and methods for preparing and using same
US5064413A (en) * 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) * 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5369155A (en) * 1989-12-28 1994-11-29 Minnesota Mining And Manufacturing Company Composite of a dispersed gel in an adhesive matrix and method for preparing same
US5270358A (en) * 1989-12-28 1993-12-14 Minnesota Mining And Manufacturing Company Composite of a disperesed gel in an adhesive matrix
US5457015A (en) * 1991-09-03 1995-10-10 Minnesota Mining And Manufacturing Company Silver halide coated organic polymeric films utilizing chitosan acid salt antistatic protection layers
US5770255A (en) * 1992-05-19 1998-06-23 Westaim Technologies, Inc. Anti-microbial coating for medical devices
US5383851A (en) * 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5399163A (en) * 1992-07-24 1995-03-21 Bioject Inc. Needleless hypodermic injection methods and device
US5520639A (en) * 1992-07-24 1996-05-28 Bioject, Inc. Needleless hypodermic injection methods and device
US5631066A (en) * 1993-01-25 1997-05-20 Chronopol, Inc. Process for making metalized films and films produced therefrom
US5534288A (en) * 1993-03-23 1996-07-09 United States Surgical Corporation Infection-resistant surgical devices and methods of making them
US5454889A (en) * 1993-08-19 1995-10-03 Ici Canada Inc. Prill coating
US5792793A (en) * 1993-11-05 1998-08-11 Meiji Milk Products Co., Ltd. Antibacterial, antifungal and antiviral agent
US5372589A (en) * 1993-11-24 1994-12-13 Davis; W. Gordon Fenestrated transparent catheter securing device and method
US6126931A (en) * 1993-12-20 2000-10-03 Surfacine Development Company, Llc Contact-killing antimicrobial devices
US5899880A (en) * 1994-04-08 1999-05-04 Powderject Research Limited Needleless syringe using supersonic gas flow for particle delivery
US5578073A (en) * 1994-09-16 1996-11-26 Ramot Of Tel Aviv University Thromboresistant surface treatment for biomaterials
US5569207A (en) * 1994-10-13 1996-10-29 Quinton Instrument Company Hydrocolloid dressing
US6022547A (en) * 1994-12-06 2000-02-08 Helene Curtis, Inc. Rinse-off water-in-oil-in-water compositions
US6187290B1 (en) * 1994-12-06 2001-02-13 Giltech Limited Physiologically acceptable foamable formulation and foam
US6010478A (en) * 1995-02-14 2000-01-04 Powderject Research Limited Trans-mucosal particle delivery
US6197351B1 (en) * 1995-06-07 2001-03-06 Robert S. Neuwirth Intrauterine chemical necrosing method and composition
US5744151A (en) * 1995-06-30 1998-04-28 Capelli; Christopher C. Silver-based pharmaceutical compositions
US6013050A (en) * 1995-10-20 2000-01-11 Powderject Research Limited Particle delivery
US6201164B1 (en) * 1996-07-11 2001-03-13 Coloplast A/S Hydrocolloid wound gel
US5945032A (en) * 1996-09-30 1999-08-31 Basf Aktiengesellschaft Polymer/hydrogen peroxide complexes
US5895419A (en) * 1996-09-30 1999-04-20 St. Jude Medical, Inc. Coated prosthetic cardiac device
US6277169B1 (en) * 1997-02-24 2001-08-21 Superior Micropowders Llc Method for making silver-containing particles
US5981822A (en) * 1997-05-02 1999-11-09 Johnson & Johnson Medical, Inc. Absorbent wound dressings
US6071543A (en) * 1997-06-02 2000-06-06 Cellegy Pharmaceuticals, Inc. Pyridine-thiols reverse mucocutaneous aging
US20020045049A1 (en) * 1997-06-20 2002-04-18 Madsen Niels Joergen Hydrophilic coating and a method for the preparation thereof
US6165440A (en) * 1997-07-09 2000-12-26 Board Of Regents, The University Of Texas System Radiation and nanoparticles for enhancement of drug delivery in solid tumors
US6123925A (en) * 1998-07-27 2000-09-26 Healthshield Technologies L.L.C. Antibiotic toothpaste
US6071541A (en) * 1998-07-31 2000-06-06 Murad; Howard Pharmaceutical compositions and methods for managing skin conditions
US6096002A (en) * 1998-11-18 2000-08-01 Bioject, Inc. NGAS powered self-resetting needle-less hypodermic jet injection apparatus and method
US6365130B1 (en) * 1998-11-23 2002-04-02 Agion Technologies L.L.C. Antimicrobial chewing gum
US20010010016A1 (en) * 1999-03-31 2001-07-26 Shanta Modak Triclosan and silver compound containing medical devices
US6258385B1 (en) * 1999-04-22 2001-07-10 Marantech Holding, Llc Tetrasilver tetroxide treatment for skin conditions
US6720006B2 (en) * 1999-06-17 2004-04-13 Bernhard Hanke Anti-microbial body care product
US20020001628A1 (en) * 1999-11-24 2002-01-03 Mikio Ito Pharmaceutical composition for preventing and/or curing digestive disorders
US20020016585A1 (en) * 2000-07-29 2002-02-07 Sachse Hans E. Catheter with a bio-resorbable coating for preventing ascending infections

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7270721B2 (en) 2003-06-23 2007-09-18 Beiersdorf Ag Antimicrobial wounddressing
US20040259445A1 (en) * 2003-06-23 2004-12-23 Beiersdorf Ag Antimicrobial composite
US8383527B2 (en) 2003-06-23 2013-02-26 Beiersdorf Ag Antimicrobial composite
US20060057369A1 (en) * 2003-06-23 2006-03-16 Beiersdorf Ag Antimicrobial composite
US20060057914A1 (en) * 2003-06-23 2006-03-16 Beiersdorf Ag Antimicrobial composite
US9101682B2 (en) 2003-06-23 2015-08-11 Beiersdorf Ag Antimicrobial composite
US20060154540A1 (en) * 2003-06-23 2006-07-13 Beiersdorf Ag Antimicrobial wounddressing
US20090092788A1 (en) * 2003-06-23 2009-04-09 Beiersdorf Antimicrobial composite
WO2006016263A3 (en) * 2004-03-03 2006-04-20 David James Field No-containing complexes
WO2006016263A2 (en) * 2004-03-03 2006-02-16 Nucryst Pharmaceuticals Corp. No-containing complexes
US20050196463A1 (en) * 2004-03-03 2005-09-08 Stiles James Alexander R. NO-containing complexes
US20120237584A1 (en) * 2006-01-13 2012-09-20 3M Innovative Properties Company Silver-containing antimicrobial articles and methods of manufacture
US9289450B2 (en) * 2006-01-13 2016-03-22 3M Innovative Properties Company Silver-containing antimicrobial articles and methods of manufacture
US20080044491A1 (en) * 2006-06-30 2008-02-21 Nucryst Pharmaceuticals Metal-containing formulations and methods of use
US20080050452A1 (en) * 2006-06-30 2008-02-28 Nucryst Pharmaceuticals Metal-containing formulations and methods of use
US20080014278A1 (en) * 2006-06-30 2008-01-17 Nucryst Pharmaceuticals Metal-containing formulations and methods of use
US20080014247A1 (en) * 2006-06-30 2008-01-17 Nucryst Pharmaceuticals Metal-containing formulations and methods of use
US8865227B2 (en) 2007-12-20 2014-10-21 Smith & Nephew (Overseas) Limited Metal carbonate particles and methods of making thereof
US20090162448A1 (en) * 2007-12-20 2009-06-25 Nucryst Pharmaceuticals Corp. Metal Carbonate Particles and Methods of Making Thereof
US9440001B2 (en) 2013-03-06 2016-09-13 Specialty Fibres and Materials Limited Absorbent materials

Also Published As

Publication number Publication date Type
EP1390013A4 (en) 2005-01-12 application
WO2002085387A2 (en) 2002-10-31 application
CA2445740A1 (en) 2002-10-31 application
US20040157073A1 (en) 2004-08-12 application
DE60210441D1 (en) 2006-05-18 grant
DE60210441T2 (en) 2006-11-16 grant
US20030054046A1 (en) 2003-03-20 application
CA2445729A1 (en) 2002-10-31 application
WO2002085384A3 (en) 2003-08-21 application
ES2261659T3 (en) 2006-11-16 grant
JP2004529929A (en) 2004-09-30 application
JP2004525980A (en) 2004-08-26 application
US20060204591A1 (en) 2006-09-14 application
CA2443587A1 (en) 2002-10-31 application
WO2002085386A3 (en) 2003-01-16 application
WO2002085387A3 (en) 2003-01-16 application
CA2445734A1 (en) 2002-10-31 application
US6939568B2 (en) 2005-09-06 grant
US6989156B2 (en) 2006-01-24 grant
EP1383520B1 (en) 2013-09-18 grant
US7087249B2 (en) 2006-08-08 grant
EP1383522B1 (en) 2006-04-05 grant
US20030099718A1 (en) 2003-05-29 application
US20020182265A1 (en) 2002-12-05 application
EP1383521A2 (en) 2004-01-28 application
EP1383520A2 (en) 2004-01-28 application
EP1390013A2 (en) 2004-02-25 application
US6723350B2 (en) 2004-04-20 grant
JP2004529930A (en) 2004-09-30 application
WO2002085299A3 (en) 2003-10-16 application
CA2445729C (en) 2013-07-02 grant
JP2005507368A (en) 2005-03-17 application
US20030086977A1 (en) 2003-05-08 application
EP1383522A2 (en) 2004-01-28 application
US20060083792A1 (en) 2006-04-20 application
WO2002085386A2 (en) 2002-10-31 application
WO2002085385A2 (en) 2002-10-31 application
WO2002085299A2 (en) 2002-10-31 application
WO2002085384A2 (en) 2002-10-31 application
US20050271743A1 (en) 2005-12-08 application
WO2002085385A3 (en) 2003-01-16 application

Similar Documents

Publication Publication Date Title
US5739286A (en) Bone augmentation material
US5037810A (en) Medical application for heparin and related molecules
US5744150A (en) Softened antimicrobial sponge material with color change indication of antimicrobial activity
Lawrence Dressings and wound infection
US7196054B1 (en) Methods for treating wound tissue and forming a supplemented fibrin matrix
Draye et al. In vitro and in vivo biocompatibility of dextran dialdehyde cross-linked gelatin hydrogel films
Ågren Studies on zinc in wound healing
US7122018B2 (en) Device and method for treatment of wounds with nitric oxide
US6187290B1 (en) Physiologically acceptable foamable formulation and foam
US20050019380A1 (en) Microbial cellulose wound dressing for treating chronic wounds
Burrell A scientific perspective on the use of topical silver preparations
Daeschlein et al. Feasibility and clinical applicability of polihexanide for treatment of second-degree burn wounds
US7005556B1 (en) Multilayer wound dressing
US5196185A (en) Collagen-based wound dressing and method for applying same
US5753251A (en) Anti-microbial coating for medical device
US6605751B1 (en) Silver-containing compositions, devices and methods for making
US6117437A (en) Pharmaceutical form for delivery of active substances to wounds
US4122158A (en) Topical therapeutic preparations
Field et al. Overview of wound healing in a moist environment
US6544548B1 (en) Keratin-based powders and hydrogel for pharmaceutical applications
Dunn et al. The role of Acticoat™ with nanocrystalline silver in the management of burns
US6458380B1 (en) Dressing and preparation delivery system
US20080311163A1 (en) Cosmetic Treatment With Nitric Oxide, Device For Performing Said Treatment And Manufacturing Method Therefor
US20050142218A1 (en) Pharmaceutical composition containing nitrate source and an acidifying agent for treating skin ischaemia
US4956350A (en) Wound filling compositions

Legal Events

Date Code Title Description
AS Assignment

Owner name: NUCRYST PHARMACEUTICALS CORP., CANADA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BURRELL, ROBERT EDWARD;WRIGHT, JOHN BARRYMORE;LAM, KAN;REEL/FRAME:013103/0918;SIGNING DATES FROM 20020702 TO 20020710